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ABSTRACT (English) 
 
YAP and TAZ are two closely related transcriptional regulators involved in tissue growth, 
stem cell maintenance and cancer. YAP/TAZ are aberrantly activated in different tumors 
where they have causative roles in initiation, progression and metastasis. However, the 
transcriptional program they activate in cancer cells remains incompletely understood. 
Therefore, we tried to dissect YAP/TAZ direct target genes in a breast cancer cell line (MDA-
MB-231 cells) by genome-wide analysis. In so doing, we discovered that YAP/TAZ mainly 
bind distal enhancers that contact target promoters through chromatin looping to activate a 
broad transcriptional program activating cell proliferation. We assessed that YAP/TAZ 
exploit TEAD proteins as DNA binding partners in breast cancer cells.  
We then focused on the interaction of YAP/TAZ and TEAD with general transcriptional 
regulators, aiming at identifying indispensible co-factors for YAP/TAZ/TEAD transcriptional 
activity at enhancers. Our findings provide new details on YAP/TAZ behaviour, and open a 
new therapeutic perspective to achieve pharmacological inhibition of YAP/TAZ by impairing 
their nuclear function.  
Part of this work has been published in Nature Cell Biology (Zanconato et al., 2015). Part is 
unpublished. 
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ABSTRACT (Italiano) 
 
YAP e TAZ sono due regolatori trascrizionali strettamente correlati, coinvolti nella crescita 
dei tessuti, nella biologia delle cellule staminali e nel cancro. Un’espressione anomala di YAP 
e TAZ è riscontrata in diversi tipi di tumori; YAP/TAZ sono infatti coinvolti nella 
formazione, nella progressione e nella crescita metastatica di molti tumori umani. Tuttavia, il 
programma trascrizionale attivato da YAP/TAZ nelle cellule tumorali non è ancora ben 
definito. Pertanto, noi abbiamo ricercato, attraverso un’analisi ad ampio spettro, i geni 
trascrizionalmente regolati da YAP/TAZ utilizzando la tecnologia della ChIP-Seq in una linea 
cellulare di tumore alla mammella (cellule MDA-MB-231). 
In questo modo, abbiamo scoperto che YAP/TAZ sono fattori che regolano la trascrizione 
genica prevalentemente legando siti enhancer che contattano i promotori dei geni regolati 
tramite il ripiegamento della cromatina. In particolare, YAP/TAZ attivano un programma di 
crescita cellulare, modulando l'espressione di centinaia di geni, come ad esempio MYC, nelle 
cellule MDA-MB-231. 
YAP/TAZ non possono legare direttamente il DNA, ma solo tramite l’interazione con fattori 
di trascrizione; in particolare, nelle cellule di tumore alla mammella, sono risultati interagire 
con i fattori di trascrizione appartenenti alla famiglia TEAD.  
In seguito, abbiamo ricercato possibili interazioni di YAP e TAZ con regolatori generali della 
trascrizione allo scopo di identificare co-fattori indispensabili per l’attività trascrizionale di 
YAP/TAZ/TEAD mediata da siti enhancer.  
I nostri risultati hanno meglio elucidato l’attività trascrizionale di YAP/TAZ, aprendo una 
nuova prospettiva terapeutica; inibire farmacologicamente YAP/TAZ, agendo sulla loro 
funzione nucleare, potrebbe infatti essere una possibile strategia di cura per il cancro. 
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INTRODUCTION 
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) 
are two closely related mammalian transcriptional regulators that shuttle between the 
cytoplasm and the nucleus to regulate transcription. YAP and TAZ are powerful regulators of 
cell proliferation, stem cell self-renewal, and fate decision and they have fundamental roles in 
organ growth, tissue homeostasis, and cancer. 
 
Signals converging on YAP/TAZ  
 
YAP/TAZ are mainly known as the key components of the Hippo pathway; nevertheless, in 
the past decade numerous publications identified YAP/TAZ as a signaling integrator of 
diverse upstream cues, such as cell polarity, mechanical cues and soluble signals (Piccolo, 
Dupont & Cordenonsi, 2014). 
 
Hippo pathway 
The Hippo pathway is an evolutionally conserved kinase cascade, firstly delineated in 
Drosophila melanogaster. Hippo signaling plays key roles in organ size control, tissue 
homeostasis and repair (Harvey, Zhang, & Thomas, 2013). 
In mammals the core components of the Hippo cascade are the kinases MST1/2 and LATS1/2.  
When the Hippo kinases are active MST1/2, together with their adaptor protein SAV1 
(Salvador homologue 1), form an active enzyme that phosphorylates and activates LATS1/2 
and their regulatory subunits MOB1A/B. Activation of the LATS1/2-MOB1A/B complex 
results in YAP/TAZ phosphorylation at several serine residues (five in YAP, four in TAZ). 
YAP/TAZ phosphorylation leads to their sequestration in the cytoplasm, binding to 14-3-3 
proteins, and proteasomal degradation mediated by the ubiquitin ligase β-TRCP (Hansen, 
Moroishi, & Guan, 2015). When the Hippo kinases are inactive, unphosphorylated YAP/TAZ 
accumulate in the nucleus where they regulate the transcription of target genes (Tremblay & 
Camargo, 2012). 
 No specific extracellular ligands or membrane receptors are known to activate the Hippo 
pathway; nevertheless multiple upstream branches of Hippo signaling control YAP/TAZ 
activity, such as  NF2/Merlin and apical cell polarity proteins (Harvey et al., 2013). 
YAP/TAZ phosphorylation by LATS is important, but not an absolute determinant of 
YAP/TAZ nuclear localization or stability. Therefore, YAP and TAZ integrate LATS-
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dependent regulation and other independent cues. 
 
Mechanical signals 
Cell shape, plasticity of the extracellular matrix (ECM), and pulling forces exerted by 
neighbouring cells impact on the cell cytoskeleton and regulate YAP/TAZ localization and 
activity. Mechanical forces are intrinsic to the architecture and geometry of the tissues and 
can affect YAP/TAZ activity. Internal forces are always in perfect equilibrium with the 
external forces dictated by ECM rigidity or traction by neighbouring cells. 
Increased cell tension (stiff extracellular environment, cell spreading, F-actin stabilization) 
induces nuclear YAP/TAZ localization, whereas loss of cellular tension (soft ECM 
environment, round cell shape, F-actin disruption) increases their cytoplasmic localization 
(Dupont et al., 2011).  
Mechanical signals are independent from Hippo kinase; they are transduced to YAP/TAZ 
through Rho-GTPase and Rho-kinase and the actomyosin cytoskeleton. YAP/TAZ-mediated 
mechanical cues are biologically relevant, as they influence cell fate decisions and 
proliferation.  
 
Cell adhesion and polarity signals 
Tissue structures manifest a highly ordered spatial architecture that in normal condition is a 
potent suppressor of YAP/TAZ activity, in part due to the activation of Hippo pathway. 
Several reports point to cell polarity, cell-cell adhesion and cell density as regulators of 
YAP/TAZ localization. 
Contact inhibition, a condition in which cells cease to proliferate when they come into 
physical contact with their neighbours, is known to strongly restrict YAP/TAZ in the 
cytoplasm (B. Zhao et al., 2007). In line, reduction of cell size leads to YAP/TAZ nuclear 
exclusion and inhibition of proliferation (Aragona et al., 2013).  
Mammalian epithelial cells adhere to one another via junction protein complexes that may 
directly inhibit YAP and TAZ; for example, α-catenin and angiomotin, two components of 
adherent and tight junctions respectively, have been shown to interact with YAP/TAZ and to 
recruit them to the cell cortex, thus preventing YAP/TAZ nuclear activity.  
Cell polarity is another potent suppressor of YAP/TAZ activity; a number of proteins that 
determine cell polarity were found to regulate YAP/TAZ, such as the Scribble-Dlg–Lgl 
basolateral complex, atypical protein kinase C and Crumbs (Varelas, 2014).For example, 
Scribble delocalization from the plasma membrane in mammary epithelial cells leads to TAZ 
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nuclear accumulation, a trait shared by a large number of malignant breast cancers 
(Cordenonsi et al., 2011). Instead, other polarity proteins contribute to YAP/TAZ repression 
by sequestering them at cell junctions, as the apical Crumbs complex (CRB) (Varelas et al., 
2010).  
 
GPRC signaling 
An important class of YAP/TAZ regulators is the G-protein coupled receptors (GPCRs). 
GPCRs detect extracellular molecules and relay signals through associated G proteins. 
According to the G protein involved and the stimulating molecules (as hormones), the activity 
of YAP/TAZ can be either down-regulated or up-regulated by GPRCs. Thus, GPCRs provide 
a large number of potential mechanisms for YAP/TAZ control, that can be either Hippo-
dependent or independent (Hansen et al., 2015). 
 
Wnt 
Recent evidences indicate that Wnt/β-catenin signaling and YAP/TAZ signaling are closely 
related (Azzolin et al., 2014). YAP/TAZ are target of the same destruction complex (the 
APC/GSK3/Axin complex) that regulates β -catenin. Without Wnt ligands YAP and TAZ are 
retained in cytoplasm in the destruction complex and mediate β-catenin degradation through 
the recruitment of β-TrCP. Instead Wnt ligands release not only β-catenin, but also YAP and 
TAZ from the destruction complex, and allow YAP/TAZ nuclear accumulation. 
 
 
YAP/TAZ in the nucleus 
 
All the upstream cues listed above converge to regulate YAP/TAZ subcellular localization. 
YAP/TAZ are found both in the cytoplasm and in the nucleus, where they regulate gene 
transcription; as such, YAP/TAZ nuclear availability is a key determinant of their function.  
The broad spectrum of YAP/TAZ regulation greatly implies a large number of genes whose 
expression can be specifically regulated by YAP/TAZ. To date, only few YAP/TAZ target 
genes, with uncertain functional significance and general relevance, have been described 
(Piccolo et al., 2014). Indeed, the number of YAP/TAZ established effectors is growing larger 
(CTGF, CYR61, ANKRD1, BIRC5, AXL, InhA, Col8a1 and others), but none can explain the 
biological effects of YAP/TAZ; as such, the transcriptional program that YAP/TAZ activate 
to achieve their biological effects remains poorly understood (Hong & Guan, 2012). 
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YAP and TAZ possess a strong transcriptional activation domain, but they do not carry a 
DNA-binding domain; so they can contact DNA only indirectly, through DNA-binding 
partners. In the nucleus, YAP/TAZ interact with DNA-binding transcription factors to form 
functional transcription complexes that recognize cis-regulatory elements and activate the 
expression of target genes.  
Several YAP/TAZ transcriptional partners have been proposed, such as Runx1/2, ErbB4, 
PPAR-g, Pax3 and T-box transcription factor 5 (TBX-5) (Pan, 2010). YAP and TAZ were 
also found to bind Smads; cytoplasmic YAP/TAZ participate in Smad2/3 cytoplasmic 
retention, even overruling the effects of high levels of TGF-B ligands (Piccolo et al., 2014). 
Moreover, p73 (a p53 family member) is potentially interesting as the p73-YAP complex is 
formed after DNA damage, leading to activation of a cell death program (Mo, Park, & Guan, 
2014). However, TEAD/TEF family of DNA-binding proteins has been established as the 
main YAP/TAZ interacting transcription factors in mammals and their homolog Scalloped in 
Drosophila (S. Wu, Liu, Zheng, Dong, & Pan, 2008; Heng Zhang et al., 2009; B. Zhao et al., 
2008). The four TEAD family members (TEAD 1-4) are widely expressed in most 
mammalian tissues and organs (Pan, 2010). A series of studies suggested that TEAD proteins 
mediate a number of YAP/TAZ functions in mammalian cells, including contact inhibition, 
epithelial-mesenchymal transition and trophectoderm development (Piccolo et al., 2014; B. 
Zhao et al., 2008). However, it is still unknown to what extent the transcriptional activity of 
YAP/TAZ overlaps with TEAD activity, and whether the YAP/TAZ and TEAD complex 
operates on specific genes, rather than on entire gene-expression programs. 
Another under-investigated issue is what takes place between the recognition of a specific 
locus by YAP/TAZ and downstream transcriptional events. It has been recently reported that 
YAP and TAZ can interact with components of the SWI/SNF chromatin remodelling complex 
and recruit NCOA6 histone methyltransferase complex to increase H3K4 methylation and 
transcription of target genes (Oh et al., 2013; Qing et al., 2014; Skibinski et al., 2014). 
YAP/TAZ-TEAD complex can also operate as transcriptional corepressors by recruiting the 
NuRD histone deacetylase complex (Kim, Kim, Johnson, & Lim, 2015). Very recently, 
Camargo and colleagues reported that YAP modulates transcription by regulating promoter-
proximal polymerase II (Pol II) pause release by interacting and recruiting the Mediator 
complex to enhancers, allowing the recruitment of the CDK9 elongating kinase (Galli et al., 
2015). 
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YAP/TAZ biological functions 
 
Early embryonic development 
Accurate control of the levels and localization of YAP/TAZ is essential for early 
developmental events. This is demonstrated by the severe phenotypes associated with ablation 
of YAP and/or TAZ genes: in mouse embryos, YAP/TAZ double null mutants die before 
implantation (Nishioka et al., 2009); YAP-/- embryos die after gastrulation, around stage E8.5 
(Morin-kensicki et al., 2006); TAZ -/- embryos display high rates of embryonic lethality, but a 
fraction of mutants develop to term and die of polycystic kidney disease and pulmonary 
emphysema (Makita et al., 2008). 
The nuclear/cytosolic distribution of YAP/TAZ defines the first cell choice in the mouse 
embryo, where embryonic cells decide to become either trophectoderm (TE) or Inner Cell 
Mass (ICM). At the blastocyst stage, YAP/TAZ accumulate in the nuclei of outer TE cells, 
while they are distributed throughout the cytoplasm in cells of the ICM. Nuclear YAP/TAZ 
control the expression of multiple genes including the induction of Cdx2, the master gene 
associated with TE fate, important to establish strong apicobasal polarity and tight junctions 
(Nishioka et al., 2009; Piccolo et al., 2014). 
 
Stem cells 
YAP/TAZ have been extensively portrayed as “stemness factors”: transgenic mice 
overexpressing nuclear YAP - or carrying mutations in Hippo pathway components - display 
dramatic embryonic organ overgrowth, potentially by expanding the number of somatic stem 
cells in those trangenic organs (Piccolo et al., 2014; Ramos & Camargo, 2012). Perhaps 
consistently, in adult tissues, YAP/TAZ are enriched in anatomical compartment containing 
stem and progenitor cells, for example in stem cell compartment of the intestinal epithelium 
(Camargo et al., 2007). Tissues such as skin and skeletal muscle show graded YAP levels 
based on differentiation status: YAP is nuclear (and thus active) in stem/progenitor cells, and 
cytoplasmic (inactive) in mature cells. Cytoplasmic restriction of YAP/TAZ is a prerequisite 
for tissue homeostasis, whereas nuclear YAP/TAZ promotes progenitor renewal and 
proliferation, essential in conditions in which stem cells need to be amplified such as tissue 
regeneration. Indeed, YAP/TAZ are essential for physiological tissue repair upon injury (Cai 
et al., 2010).  
This spatial organization indicates that the transcriptional activity of YAP/TAZ could be 
important in the maintenance of stem cell traits in normal tissues (Ramos & Camargo, 2012). 
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Our group recently published that transient expression of exogenous YAP or TAZ in primary 
differentiated mouse cells could induce conversion to tissue-specific stem/progenitor cell state 
ex vivo (Panciera et al., 2014), highlighting an unprecedented connection between YAP/TAZ 
and cell plasticity and between YAP/TAZ and the somatic SC state.  
 
Cancer 
A number of studies suggest that YAP/ TAZ play causative roles in tumor initiation, 
progression and metastasis in various human organs, including breast, colon, lung and liver. 
Characterization of human tumor samples highlighted that YAP/TAZ are frequently 
overexpressed and activated during tumorigenesis. Moreover, aberrant YAP and/or TAZ 
nuclear localization, or high expression of YAP/TAZ target genes, are associated with poor 
outcome in large datasets of breast and colon cancer patients (Piccolo et al., 2014). 
YAP/TAZ oncogenic potential lies in their capacity to direct cell proliferation, cell survival 
and cancer stem cell fate (Mo et al., 2014). Sustained activation of YAP/TAZ promotes 
aberrant cell proliferation (Camargo et al., 2007) and an increased resistance to cell death (B. 
Zhao et al., 2012). Moreover, YAP/TAZ are active in the cancer stem cell (CSC) fraction, and 
they are functionally instrumental and required for CSC expansion (Piccolo et al., 2014). It 
has been reported that YAP/TAZ can reprogram non-stem tumor cells into cells with full CSC 
attributes (Bartucci et al., 2015; Cordenonsi et al., 2011).  
An additional cancer-associated trait regulated by YAP/TAZ includes the ability to induce 
chemoresistance; tumor cells with activated YAP/TAZ display indeed resistance to 
chemotherapeutic drugs. In a breast cancer contest, TAZ sustains survival of cancer stem cells 
treated with conventional chemotherapeutics, such as paclitaxel and doxorubicin, both in vitro 
and in mouse models (Bartucci et al., 2015; Cordenonsi et al., 2011). 
Furthermore, YAP/TAZ influence the chemical, physical, and cellular composition of the 
tumor microenvironment; in some context, they induce the secretion of growth factors, 
matricellular proteins and interleukins to orchestrate crosstalk from cancer cells and normal 
cells (Piccolo et al., 2014).  
Even though YAP/TAZ are frequently deregulated in human tumors, no germline or somatic 
mutations have been identified in YAP or TAZ, nor in most of the components of the Hippo 
pathway. Indeed, with the exception of inherited disorders associated with NF2, somatic 
mutations in the core Hippo members are extremely rare in human tumors (Harvey et al., 
2013). Considering that YAP/TAZ activation cannot be explained by mutations in Hippo 
pathway components, other YAP/TAZ modulations should be crucial for their activity in 
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human cancers. Mechanical cues have an important role in YAP/TAZ regulation during 
tumorigenesis, where integrity of tissues is disturbed. YAP/TAZ can be re-activated by cell 
shape distortions or attachment to an increasingly abnormal and rigid ECM (Zanconato, 
Cordenonsi, Piccolo, 2016). That said, the transcriptional programs induced by YAP/TAZ 
that lead to cancer development is unknown (Moroishi et al., 2015). 
 
 
Anti-YAP/TAZ therapeutic interventions 
 
YAP/TAZ are broadly activated in different human cancers, where they are involved in many 
aspects of cancer biology. Further, YAP/TAZ are largely dispensable for normal homeostasis 
in the healthy tissue whereas they are essential for tumor development. These evidences make 
them appealing therapeutic targets for cancer (Piccolo et al., 2014). Genetic evidences in 
mouse models, collectively indicating that inactivation of YAP/TAZ in several adult organs -
including breast, liver, pancreas, skin and intestine- renders those tissues immune to cancer 
emergence or progression (Azzolin et al., 2014; Chen et al., 2014; Zhang et al., 2014). 
To identify candidate drugs able to modulate YAP/TAZ activity, most efforts have been 
dedicated to YAP/TAZ upstream inducers and signaling pathways. Considering that they 
integrate several signaling cascades, many therapeutic options are emerged, targeting 
mechanotransduction, the energy metabolism (statins), GPCR signaling (Gα inhibitors) and 
turning off Wnt signaling (Tankyrase inhibitors) (Zanconato, Battilana, Cordenonsi, & 
Piccolo, 2016). However, the complexity of YAP/TAZ regulation makes this approach poorly 
efficient, since cancer cells may use different combinations of upstream inputs in a tumor-
specific way, and even between different areas of the same lesion (Zanconato, Cordenonsi, 
Piccolo, 2016). Since all upstream regulators ultimately impact on YAP/TAZ nuclear 
availability and transcriptional responses, designing compounds able to interfere at these 
levels may represent a “universal” anti-YAP/TAZ inhibition. This approach may also display 
an added advantage of reduced toxicity compared to drugging upstream signaling molecules 
that might lead to pleiotropic effects. 
Verteporfin (VP) is an example of YAP/TAZ targeting molecule that affects transcriptional 
activity. This compound belongs to the porphyrin family, and it is able to inhibit the physical 
association between YAP and TEAD proteins. From the literature is known that VP can 
reduce liver overgrowth in mice upon YAP overexpression or NF2 knockout (Liu-chittenden 
et al., 2012). Moreover, VP has been successfully used to restrain the growth of uveal 
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melanoma cells in an orthotopic mouse model (Yu, Zhang, & Guan, 2014) and of pre-
established xenografts of prostate cancer cells bearing activated YAP (Nguyen et al., 2015). 
However, a recent study reported that VP suppresses the proliferation of cancer cells by 
inducing toxicity, acting independently of YAP (H. Zhang et al., 2015). 
Irrespectively, targeting YAP/TAZ transcriptional mechanisms is a potentially promising area 
to design new therapeutic interventions. For this, the mechanisms by which nuclear 
YAP/TAZ control gene expression needs to be further investigated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   12	  
AIM OF THE PROJECT 
 
Recently YAP/TAZ activity has been the main object of investigation in our laboratory, in 
particular in breast cancers (BC).  It has been reported that YAP/TAZ have several roles in 
breast cancer development; yet, the transcriptional program they activate to promote cell 
transformation is still poorly understood. The aim of our project is to collect genome-wide 
data about YAP/TAZ transcriptional activity in cancer cells, use it to dissect the mechanisms 
by which YAP/TAZ exert their oncogenic functions and derive from this analysis new 
strategies of intervention. 
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RESULTS 
 
Identification of YAP/TAZ DNA binding sites at genomic level in a breast cancer cell 
line. 
 
We chose MDA-MB-231 cells, as the main model for the investigation of YAP/TAZ 
transcriptional program. This represent a model of Triple Negative Breast Cancer that is 
considered one of the most aggressive and heterogeneous forms of mammary tumors. 
Inportantly, these cells bear genetic inactivation of the Hippo pathway (NF2 null) causing 
constitutive activation of YAP/TAZ (Aragona et al., 2013); furthermore, these cells are 
almost mesenchymal and do not express the classic cell-cell adhesion molecules that are 
responsible of Hippo activation in normal epithelial cells. Finally, they easily adopt a well-
spread morphology, translating in increased YAP mechanotransduction. In sum, MDA-MB-
231 cells concentrates a number of features that potently sustain YAP/TAZ activity. To 
elucidate how YAP/TAZ regulate gene expression in these cells, we decided to identify the 
genomic loci bound by YAP/TAZ through chromatin immunoprecipitation assays followed 
by next-generation sequencing (ChIP-seq).  
      
ChIP-seq: method overview 
Chromatin immunoprecipitation is a method to detect interactions between proteins and 
genomic DNA (Figure 1A) (Kharchenko, Tolstorukov, & Park, 2008; Schmidt et al., 2009). 
Living cells are reversibly crosslinked by formaldehyde, locking transcription factors to their 
DNA binding sites in the genome. Cells are chemically lysed to isolate cell nuclei and these 
nuclei are then sonicated, in order to obtain chromatin fragments sized 200-600 base pairs 
through high-frequency sound waves (Figure 1B).  Specific antibodies are used to 
immunoprecipitate transcription factors of interest together with their bound DNA fragments. 
These protein-DNA complexes are then isolated by protein A-functionalized magnetic beads. 
DNA is eluted from the magnetic beads and the covalent DNA–protein crosslinks are 
reversed by heating. Enriched DNA fragments are purified for downstream analysis to 
identify the sequences bound by the protein. Usually, ChIP is coupled with quantitative real-
time PCR (ChIP-qPCR), genomic microarray (ChIP-chip) or deep sequencing (ChIP-seq).  
ChIP-seq allows the unbiased identification of transcription factor binding sites in the 
genome. Common “adapter sequences” are ligated to the ends of ChIPed DNA. DNA 
fragments of the appropriate size range (150-300 base pairs) are selected by running the DNA 
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in an agarose gel to set the binding site resolution. Then, the library is amplified by bridge 
PCR, where adaptors provide a target sequence for the primers to generate the template for 
sequencing. In our case, the amplicons were sequenced by Illumina platform. For ChIP-seq 
experiments, short reads (40 base pairs) from one end of the fragments provide sufficient 
information (Figure 1C). The recommended sequencing depth is ~20 mln uniquely mapping 
reads/sample; an increased depth of coverage allows the detection of more sites that have 
lower levels of enrichment over the genomic background.  
Uniquely mapping sequences are aligned to the genome and the alignment of sequenced tags 
to the genome results in two peaks (one for the positive and one for the negative DNA strand) 
that flank the binding region of the protein of interest. These two strand-specific peaks of tags 
are combined to generate an approximate profile of fragment distribution. Then, a “peak 
caller” algorithm scans the genome to identify regions that are significantly enriched in the 
ChIP sample relative to the experimental control. The final output consists in genome 
locations that represent likely binding sites of the protein of interest.  
 
Chromatin immunoprecipitation of endogenous YAP/TAZ 
The reliability of a ChIP experiment depends on the specificity and efficiency of the 
antibodies in recognizing and immunoprecipitating the target protein. Thus we performed trial 
experiments to assess the capacity of antibodies to immunoprecipitate endogenous YAP/TAZ 
from cross-linked chromatin. We used a monoclonal antibody targeting YAP (abcam, 
ab52771) and polyclonal antibodies targeting TAZ (sigma aldrich, HPA007415), both raised 
in rabbit. As negative control, we performed the immunoprecipitation with pre-immune 
immunoglobulins produced in rabbit. We isolated chromatin from MDA-MB-231 cells and 
we performed an immunoprecipitation experiment with the selected antibodies. After the 
recovery and elution of the immunoprecipitated protein-DNA complexes, we checked the 
result of the immunoprecipitation step by western blot (Figure 2A). The YAP monoclonal 
antibody specifically recognized and immunoprecipitated YAP, whereas TAZ polyclonal 
antibodies bound both YAP and TAZ, probably due to the high homology between the two 
proteins. In a second experiment, we performed ChIP with the same antibodies from 
chromatin obtained from MDA-MB-231 cells transfected with control or YAP/TAZ siRNAs. 
As read-out of the specificity of these experiments, we carried out quantitative real-time PCR 
on the promotorial sequences of known YAP/TAZ target genes (CTGF and CYR61) (ChIP-
PCR). As shown in Figure 2B, specific pull-down of YAP/TAZ bound-DNA could be 
detected from unmanipulated cells, but not from YAP/TAZ-depleted cells. In no case, 
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negative control ChIPs with pre-immune rabbit IgGs gave any signal (Figure 2B). As further 
control, a genomic fragment belonging to the β-globin locus (which is not expressed in MDA-
MB-231 cells, and is thus expected to be devoid of functional YAP/TAZ binding sites) is 
poorly amplified in all samples. Overall, we were confident that the antibodies could be used 
to reliably identify YAP/ TAZ binding sites genome-wide. 
 
YAP/TAZ ChIP-seq 
Having established that the two antibodies for YAP and TAZ are specific and efficient, we 
proceeded with ChIP-seq experiment. We performed chromatin immunoprecipitation from 
MDA-MB-231 cells with both YAP/TAZ polyclonal antibodies and with pre-immune rabbit 
IgGs as a negative control. We carried out two independent experiments, so that we could 
define as YAP/TAZ binding sites only those sequences that were bound by YAP/TAZ in both 
replicas (but not in the two negative control samples). We verified the enrichment of known 
YAP/TAZ-bound sequences in ChIPed DNA by qPCR to make sure of the experiments’ 
quality as already detailed in Figure 2.  
ChIPed DNA samples were processed for deep sequencing in the laboratories of IGA (Istituto 
di Genomica Applicata, Udine). About 60 x 106 reads were obtained from each sample 
(Figure 3A). Bioinformatic analysis was performed by our collaborators at the University of 
Modena (Mattia Forcato and Silvio Bicciato). Non-redundant sequences that could be mapped 
to a single site of the human genome were used to identify YAP/TAZ binding sites. After 
aligning to the human genome ChIP-seq reads from two replicate experiments, we identified a 
total of 7710 and 9798 regions bound by the monoclonal YAP antibody and the polyclonal 
TAZ antibodies, respectively. 7107 peaks were identified with both antibodies (Figure 3B). 
Given the high similarity between YAP and TAZ and their functional redundancy, we 
decided to focus on the common set of binding sites, that we renamed "YAP/TAZ" peaks. As 
to the antibody-specific peaks, we do not exclude that they might well represent YAP-specific 
or TAZ-specific binding sites but, for this work, we decided to sidestep them in favor of the 
genomic regions providing the highest confidence. 
We scanned the ChIP-seq profiles and found that YAP/TAZ peaks were present on the 
promoters of previously established YAP/TAZ direct targets, thus validating our ChIP-seq 
procedure (Figure 3C). The plot of the negative control sample, instead, displayed few tags 
aligned with the same regions, without any appreciable difference with background noise. By 
ChIP-qPCR, we validated that YAP/TAZ antibodies were truly able to bind some of the 
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newly discovered cis-regulatory regions from control cells, but not from YAP/TAZ-depleted 
cells (Figure 3D). 
 
Distribution of YAP/TAZ binding sites in the genome 
 
One important step to understand how YAP/TAZ regulates transcription is to characterize 
their DNA-binding sites. In particular, defining genome-wide distribution of YAP/TAZ 
binding sites could be useful to make inferences about their activity. Therefore, we analyzed 
the position of YAP/TAZ binding sites referred to genes annotated in the human genome, to 
investigate in which genomic regulatory regions they are preferentially located. In detail, we 
evaluated the distance of each peak from the closest transcription start site (TSS) using 
annotatePeakInBatch function of ChIPpeakanno R package and GENCODE annotation 
version 16; only genes classified as protein coding were considered (done in collaboration 
with Mattia Forcato). We found that YAP/TAZ are preferentially bound far from TSS. 
Indeed, only a small fraction of peaks (3.3%) mapped close (±1 kb) to TSS, whereas the vast 
majority of peaks (~85%) were located farther than 10kb from the closest TSS (Figure 4A, 
B).  
Due to their remote location, we asked whether most YAP/TAZ peaks are located in 
enhancers. Enhancers are short DNA fragment that are able to increase transcription of a 
target gene.  They can exert their function over long distances, either from upstream, 
downstream, or within a transcriptional unit.  Enhancers can be distinguished from promoters 
by their epigenetic features (Calo & Wysocka, 2013); enhancers are marked by 
monomethylation of histone 3 at lysine 4 (H3K4me1), whereas trimethylation at the same 
residue of histone 3 (H3K4me3) identifies promoters. In their active state, enhancers also 
show acetylation on H3K27 (H3K27ac). The distribution of histone post-translational 
modifications in the genome can be assessed by ChIP-seq with antibodies that specifically 
recognize the modified epitopes. We used published ChIP-seq datasets for H3K4me1, 
H3K4me3, H3K27ac in MDA-MB-231 cells to obtain a map of promoters and enhancers 
(Rhie et al., 2014): H3K4me3 peaks close to a TSS (±5 kb) were defined as promoters, 
whereas H3K4me1 peaks were defined as enhancers; regions with the co-presence of 
H3K4me1 and H3K4me3 peaks were defined as promoters or enhancers after the evaluation 
of the proximity to a TSS and the comparison of the enrichment signals. Promoters or 
enhancers were defined as active if overlapping with H3K27ac peaks. Peaks without any of 
the previous characteristics were defined as "not-assigned".  
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We used bioinformatic tools to compare this published map of epigenetic marks with our 
YAP/TAZ ChIP-seq data (Figure 4C). We found that only a very small fraction (3.6%) of 
YAP/TAZ peaks are located on promoters (H3K4me3). Instead, about 91% of peaks are 
located in enhancer regions (H3K4me1); most of these regions (96.5%) are in an active 
transcriptional state (H3K27ac) (Figure 4D). 
DNA regions that actively regulate transcription are predominantly found in sites of 
accessible chromatin, characterized by eviction of nucleosomes. Therefore we also compared 
the YAP/TAZ bound regions with the nucleosome-free regions of MDA-MB-231 cells. These 
data were already available from previously published FAIRE-Assays (Rhie et al., 2014). 
Formaldehyde-assisted identification of regulatory elements followed by deep sequencing 
(FAIRE–seq) is a method used for determining genomic open regions, unoccupied by 
nucleosomes, whereby cells are chemically crosslinked with formaldehyde, chromatin is 
sheared by sonication and nucleosome depleted DNA molecules are separated from DNA 
regions crosslinked to nucleosomes by phenol-chloroform extraction (the latter are trapped in 
the organic phase) and then sequenced.  We found that that >80% of the YAP/TAZ bound 
active enhancers display reduced nucleosome occupancy at the peak center (Figure 4E). 
 
 
Association of YAP/TAZ peaks to enhancer elements 
 
As our goal is – ultimately – to identify YAP/TAZ target genes, we next sought to link 
YAP/TAZ peaks to the promoters they regulate. All the peaks located in promoter regions, 
that corresponded to YAP/TAZ peaks close to a TSS (± 5kb), and whose summit was 
overlapping with H3K4me3 peaks, were assigned to the nearest gene (Figure 5A). 
However, we reasoned that this proximity criterion was questionable for the vast majority of 
YAP/TAZ peaks located in enhancers. Enhancer elements can be very far away from their 
target promoters; enhancers regulate target promoter by physically associating to them and 
doing so typically by “skipping” neighbouring genes. The logic of enhancer-promoter 
interaction is independent of the linear proximity and relies on long-distance chromatin 
looping that defines the 3D organization of the genome. Therefore, we committed to identify 
the promoters that are in physical contact with YAP/TAZ-occupied enhancers.    
Interactions between distant chromatin regions such as promoters and enhancers can be 
detected with chromatin conformation capture (3C) technologies. These methods aim to 
generate a 3D map of chromosomes on the basis of the frequency at which genomic loci are 
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in close proximity inside the nucleus. The initial step includes fixation of cells with 
formaldehyde to crosslink chromatin regions that are in close spatial proximity. The 
chromatin is then fragmented by restriction enzyme digestion to generate small complexes of 
protein and DNA. A ligation reaction is then performed: in this step interacting DNA 
fragments are turned into a single hybrid DNA molecule; chromatin is highly diluted before 
digestion, so that only DNA fragments that are covalently linked together form ligation 
products. The hybrid DNA molecules are purified and analysed to identify the distant 
genomic regions that were close to each other in the nucleus.  
Depending on the method used to reveal the identity of the interacting DNA sequences, 3C 
based method can reach different levels of resolution. At the highest resolution (Hi-C), all 
ligation products are identified by next-generation sequencing, thus allowing to map virtually 
all the interaction in the genome in an unbiased manner.  
High-resolution map of chromatin interactions (Hi-C) has been recently produced from 
human cells (Jin et al., 2013). In detail, Jin and colleagues performed Hi-C in human primary 
fibroblasts (IMR90 cells) to detect genome-wide 3D interactions. By bioinformatic 
algorithms, they filtered for functional interactions -not random- determining over one-
million long-range chromatin interactions at 5-10 kb resolution. Also, they uncovered general 
principles of chromatin organization at different types of genomic features. Secondly, they 
used their map to predict enhancers-promoter pairs with great accuracy. Therefore, 
considering that the large majority of these long-range chromatin interactions are conserved 
across cell types (Rao et al., 2014), we decided to use above published map of enhancer-
promoter pairs to identify the target promoters of YAP/TAZ-bound enhancers (Figure 5B). 
We assigned enhancer peaks to promoters that can physically interact with them according to 
high-resolution chromatin conformation capture data. Therefore, we obtained a list of 
candidate YAP/TAZ direct targets (TABLE 1). But which one is indeed functionally induced 
in MDA-MB-231 cells?  
 
 
Identification of YAP/TAZ direct target genes 
 
To define what fraction of the putative YAP/TAZ target genes identified above is regulated 
by YAP/TAZ, we focused on gene expression profiles of MDA-MB-231 cells were 
previously generated in our laboratory with Affymetrix Microarrays. Cells were transfected 
with control siRNA or two different pairs of YAP/TAZ siRNAs to identify genes whose 
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expression depends on YAP/TAZ activity. We found that YAP/TAZ knockdown 
downregulates the expression of about 1500 transcripts in MDA-MB-231 (out of more than 
18000 detected transcripts) (Figure 6A). A similar number of transcripts were upregulated, 
indicating the potential of YAP/TAZ to either directly or indirectly negatively regulate gene-
expression. In any case, we focused only on genes that are activated by YAP/TAZ, to 
conform in this first exploration to the more established role of YAP/TAZ as transcriptional 
co-activators.  
We compared the list of genes with YAP/TAZ binding sites on their cis-regulatory regions 
obtained above with the gene expression data. Of YAP/TAZ positive target genes (1534), 435 
(28%) are associated to YAP/TAZ peaks. These are bona-fide YAP/TAZ direct target genes. 
The vast majority of these (86%) are regulated by YAP/TAZ from distant enhancers. Notably, 
most (58%) of YAP/TAZ-occupied enhancers are located farther than 100,000 bp from the 
corresponding TSS (Figure 6B). 
 
 
A YAP/TAZ-regulated transcriptional program driving cell proliferation 
 
YAP/TAZ direct target genes are regulators and effectors of cell growth 
We performed gene ontology (GO) annotation of YAP/TAZ direct targets to identify the main 
biological processes regulated by YAP/TAZ through the functions of the genes they regulate. 
The Gene Ontology (GO) project has described genes in biological databases with "terms" 
that provide functional information about the gene product. Each gene in a list can be 
annotated with GO terms; then, the GO annotations can be used to determine which biological 
processes, molecular functions, and/or subcellular locations are significantly over-represented 
in a group of genes. A GO term - and the function it describes - is "enriched" in a set of genes 
(for example, positive YAP/TAZ targets) when a higher proportion of genes with that 
annotation are present among the differentially expressed genes compared to a “background” 
set of genes (for example, all the genes expressed by the cells being examined). 
We used DAVID (Database for Annotation, Visualization and Integrated Discovery) to 
identify enriched GO terms associated with direct YAP/TAZ positive target genes. A large 
fraction (154 genes, 36%) resulted to be linked with cell cycle progression. Other positive 
targets (14% of the total) are connected to RNA metabolism and RNA transport. No other 
biological processes were significantly regulated by YAP/TAZ (Figure 7A).  
	   20	  
Overall, GO annotation indicated that YAP/TAZ activate a growth program in breast cancer 
cells, in line with their well-established roles in organ growth and cell proliferation. Genes in 
the YAP/TAZ growth program encode for proteins directly involved in specific steps of the 
cell cycle. We could identify genes playing roles in the assembly of the licensing complex, 
DNA synthesis and DNA repair (e.g. CDC6, GINS1, MCM3, MCM7, POLA2, POLE3, 
TOP2A, RAD18), transcriptional regulators of the cell cycle (e.g. ETS1, MYC, MYBL1), 
cyclins and their activators (CCNA2 and CDC25A), and completion of mitosis (e.g. CENPF, 
CDCA5, KIF23).  
First of all, we validated a subset of these new YAP/TAZ target genes by qRT-PCR using 
TaqMan Low Density Arrays. We quantified the expression of 46 new target genes 
(expression levels are normalized to GAPDH) in MDA-MB-231 cells transfected with 
YAP/TAZ siRNAs. Both YAP/TAZ siRNA mixes efficiently downregulated new targets in 
two biological replicates (Figure 7B).  For a subset of genes, the downregulation of the 
corresponding proteins was also verified by Western blot (Figure 7C).  
All the genes in the YAP/TAZ growth program were associated with at least one YAP/TAZ 
peak located on enhancers. We experimentally re-confirmed by ChIP-qPCR the presence of 
YAP/TAZ on a selection of these enhancers (Figure 7D). 
 
MYC and TOP2A promoters are in contact with YAP/TAZ-occupied enhancers via chromatin 
looping 
The procedure we used to “connect” YAP/TAZ-occupied enhancers with their target 
promoters was based on chromatin conformation data obtained from human lung fibroblasts. 
The loop structure was reported to be conserved across histotypes (Rao et al., 2014); yet, as 
proof of concept, we decided to verify the interaction between some enhancer-associated 
YAP/TAZ binding sites and their predicted in our cellular system. 
We selected two representative targets belonging to the YAP/TAZ growth program, TOP2A 
and MYC. As shown in figure 8A no YAP/TAZ peaks are present close to the TSS of MYC 
gene. However, several enhancers that are predicted to interact with MYC or TOP2A 
promoters were occupied by YAP/TAZ in our ChIP-seq experiment. 
We performed chromatin conformation capture (3C) analysis in MDA-MB-231 cells (Bodega 
et al., 2009). We digested crosslinked chromatin with HindIII, ligated DNA regions that were 
in close proximity and purified hybrid DNA molecules. We then detected the ligation 
products by PCR. We designed PCR primers to measure the frequency of interaction of 
TOP2A and MYC TSS with a wide region surrounding the relative candidate enhancers. A 
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common reverse primer (called "anchor") was designed to anneal in the proximity of a 
HindIII restriction site near promoter; several forward primers (called "preys") were designed 
to flank HindIII sites in the chromosomal regions containing YAP/TAZ-occupied enhancers. 
As amplification efficiency may not be the same for all primer pairs, a reference template was 
generated by mixing and ligating bacterial artificial chromosomes spanning the genomic 
regions of interest, and the amount of PCR products obtained from the 3C template was 
normalized to the reference template. As shown in figure 8B HindIII fragments close to 
YAP/TAZ peaks on two MYC candidate enhancers display a higher ligation frequency with 
MYC promoter, compared with more distal sequences, showing that these YAP/TAZ-bound 
enhancers actually interact with MYC promoter in MDA-MB-231 cells. We obtained similar 
results with TOP2A TSS and two of its predicted enhancers (Figure 8C).  
We then asked whether YAP/TAZ actually regulate the activity of these enhancers. 
Transcriptionally active chromatin is marked by acetylation on K27 residue of histone 3. 
Thus, we performed ChIP-qPCR experiments to compare the levels of H3K27ac (normalized 
to total H3 levels) in MDA-MB-231 cells transfected with control or combined YAP/TAZ 
siRNAs. In YAP/TAZ-depleted cells, the level of H3K27ac decreased on MYC and TOP2A 
enhancers (Figure 8D). Overall, data suggest that YAP/TAZ recruitment to enhancers is 
functional for their activation, and thus for the transcription of downstream target genes. 
  
MYC is a mediator of YAP/TAZ proliferative activity 
As proof of concept of the biological validity of our findings, we studied in more depth the 
role of MYC as YAP/TAZ-regulated gene. A large body of evidence shows that MYC is one 
of the best-established factors that promote cell cycle progression and Myc deregulation is a 
major driving force of human tumorigenesis (Dominguez-Sola & Gautier, 2014). In line with 
this notion, we verified that MYC depletion with two independent siRNAs reduced the 
growth rate of MDA-MB-231 cells (monitored by crystal violet staining), with a larger 
fraction of cells blocked in the G1 phase of the cell cycle (as determined by cytofluorimetric 
analysis of DNA content) (Figure 9A-C). 
To better define the role of MYC as a mediator of cell proliferation downstream of 
YAP/TAZ, we performed a rescue experiment in which we overexpressed MYC cDNA in 
YAP/TAZ-depleted cells. MDA-MB-231 cells were transduced with lentiviral vectors 
carrying MYC or EGFP coding sequences under the control of a tetracycline response 
element (TRE), together with a vector encoding the doxycycline responsive transactivator 
rtTA, so that MYC (or EGFP) expression was induced only upon doxycycline administration 
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(Figure 9D). We transfected these cells with a control siRNA or anti-YAP/TAZ siRNA, and 
we monitored cell growth and cell cycle progression in the presence or absence of 
doxycycline. As shown in figure 9E, YAP/TAZ depletion leads to an almost complete growth 
arrest; MYC re-expression triggered a partial rescue of cell proliferation and allowed 
progression to the S-phase of the cell cycle in YAP/TAZ-depleted cells; EGFP induction had 
no effect. As a comparison, reintroduction of YAP or TAZ in YAP/TAZ-depleted cells 
completely rescued cell growth (Figure 10 N,0). This indicated that although MYC represents 
an important functional effector of YAP/TAZ in MDA-MB-231 breast cancer cells, 
YAP/TAZ orchestrate cell growth by controlling a number of other direct targets.   
 
 
Genome-wide recruitment of YAP/TAZ to chromatin through TEAD factors 
 
YAP/TAZ cannot interact with DNA by themselves because they do not possess a DNA 
binding domain. They rely on DNA binding factors to exert their transcriptional functions. 
Several TFs have been proposed to mediate YAP/TAZ interaction with chromatin (p73, 
Runx2, Smad, TEAD/TEF transcription factors) (Piccolo et al., 2014). In particular, TEAD 
proteins are known to be functional for YAP/TAZ-induced oncogenic transformation; 
however, we had no cues about the real extent of YAP/TAZ-TEAD interaction or the 
relevance of other DNA-binding partners when all the genome is taken into account, rather 
than specific loci or functions.  
DNA binding proteins recognize specific DNA sequences, called motifs. Therefore, the 
identity of YAP/TAZ partners can be inferred from the nucleotide sequence of YAP/TAZ 
peaks, found by ChIPseq. We used bioinformatic tools to search for recurrent motifs in the 
sequences bound by YAP/TAZ. Algorithms for de novo motif finding scan a pool of input 
DNA sequences (we used 500 bp sequences centred at the summit of YAP/TAZ binding sites) 
and annotate enriched “words” that recur with a higher frequency compared with a pool of 
background (random) 500bp DNA fragments. Then, enriched “words” are compared with a 
database of motifs to identify their cognate TF. This analysis revealed that the most enriched 
motif in YAP/TAZ peaks matched the consensus sequence for TEAD binding sites (62%) 
(Figure 10A). This percentage further increased (~75%) if we extended the search to known 
TEAD-responsive elements (i.e. if we scanned YAP/TAZ peaks looking for known TEAD 
motifs) (Figure 10B). Furthermore, TEAD motif frequently occupied the summit of 
YAP/TAZ peaks (the point where the signal is highest, where the protein is assumed to sit), 
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suggesting that TEADs might be the platform through which YAP/TAZ bind DNA in a large 
majority of peaks in MDA-MB-231 cells (Figure 10C).  
The presence of the motif indicates that a chromatin segment can be bound by a TF, but it is 
not predictive of real binding. Thus, to support above bioinformatics results and verify if 
TEAD factors really co-occupy DNA sites with YAP/TAZ, we performed ChIP-seq for 
endogenous TEAD4 in MDA-MB-231 cells. We chose TEAD4 because it is highly expressed 
in MDA-MB-231 cells; furthermore a good ChIP-grade TEAD4 antibody was available, 
allowing us to immunoprecipitate the endogenous protein. Indeed, we performed a 
preliminary validation experiment, and we verified that TEAD4 antibody specifically 
enriched ANKRD1 and CTGF promotorial sequences in ChIP’d DNA from control MDA-
MB-231 cells, but not from TEAD4 depleted cells (Figure 10D).  
We prepared sequencing libraries from two independent chromatin immunoprecipitations 
with TEAD4 antibody. We obtained 8406 TEAD4 peaks. Similarly to YAP/TAZ, TEAD4 
resulted to be located far from TSS, most likely on enhancer elements.  
We then compared YAP/TAZ and TEAD4 ChIP-seq data. 5522 YAP/TAZ binding sites 
(78%) overlapped with TEAD4 peaks, and the summits of TEAD4 peaks are located at the 
summits of the corresponding YAP/TAZ peaks (Figure 10E-G). By measuring peak signals, 
we also noticed a strong linear correlation between the strengths of TEAD4 and YAP/TAZ 
binding, suggesting that the more TEAD4 binds to DNA the more YAP/TAZ are associated to 
the same element (Figure 10H).  
To verify if TEAD is instrumental for YAP/TAZ binding to chromatin, we performed a ChIP-
qPCR experiment for YAP in TEAD-depleted cells. YAP recruitment to DNA was strongly 
decreased in all tested loci in the absence of TEAD proteins, reinforcing the notion that 
TEADs mediate YAP/TAZ recruitment to chromatin (Figure 10I). 
 
The large majority (85%) of direct YAP/TAZ targets, including those controlling cell cycle 
progression, are associated with TEAD4 peaks. To investigate if large part of the YAP/TAZ 
transcriptional and biological effects depended on TEAD factors, we monitored the effects of 
TEAD 1/2/3/4 knockdown in MDA-MB-231 cells (validated by gene expression, Figure 
11A). We analysed gene expression levels YAP/TAZ targets by custom TaqMan Low 
Density Arrays (expression levels are normalized to GAPDH) (Figure 11B). TEAD depletion 
with two siRNAs mixes efficiently downregulated YAP/TAZ targets involved in cell cycle 
control. Functionally, TEAD downregulation caused cells to slow down proliferation and rest 
in the G1 phase of the cell cycle (Figure 11 C, D). In line, overexpression of a mutant YAP 
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(or TAZ) that is defective for TEAD-binding cannot rescue proliferation in YAP/TAZ- 
depleted MDA-MB-231 cells, whereas overexpressed wildtype YAP or TAZ can fully 
substitute the endogenous proteins (Figure 11 E, F). 
Summing up, YAP/TAZ biological effects in MDA-MB-231 cells are mediated by TEAD 
transcription factors, which were detected in the vast majority of YAP/TAZ binding sites and 
are required for YAP/TAZ binding to DNA. 
 
 
YAP/TAZ as enhancer-associated transcription factors: focusing on Brd4  
 
Summing up, our genome-wide analysis has revealed some general features of YAP/TAZ 
transcriptional activity. ChIP-seq data for YAP/TAZ and TEAD4 revealed that YAP/TAZ 
interaction with TEAD (previously demonstrated for a few, well characterized target genes, 
such as CTGF) extends to the vast majority (~80%) of YAP/TAZ binding sites. Second, 
YAP/TAZ and TEAD bind enhancers, which are usually actively engaged in transcriptional 
regulation (H3K27ac positive).  
While we were carrying out this study in breast cancer cells, other groups obtained similar 
results in different cellular contexts. Stein et al. performed YAP and TEAD1 ChIP-seq in 
glioblastoma cells; they reported that 90% of YAP peaks are co-occupied by TEAD, and that 
only 4% of YAP/TEAD binding sites are located within 2kb of a TSS, whereas most of them 
are located on distal H3K27ac-positive regions; these results are strikingly similar to our own. 
Galli et al. profiled YAP, TEAD1 and TEAD4 chromatin occupancy in cholangiocarcinoma 
cells. The authors retrieved a small number of YAP binding sites compared to TEAD peaks 
(847 vs 11827); anyway, all YAP peaks had an overlapping TEAD peak and were located 
>20kb away from the closest TSS. In the same study, the authors observed that YAP-positive 
enhancers displayed a significantly higher density of H3K27 acetylation and H3K4 
monomethylation compared to the average signal at active enhancers not occupied by YAP, 
that are features of the so-called super-enhancers (Galli et al., 2015).  Super-enhancers are 
exceptionally large enhancer domains, containing clusters of “concatenated” enhancers; they 
display an unusually strong enrichment for the binding of transcriptional co-activators, such 
as Mediator (Med1), the histone acetyltransferases p300 and CBP or chromatin factors such 
as cohesion. Super-enhancers are occupied by master transcription factors and associated with 
key cell type-specific genes, implicating super-enhancers in the control of mammalian cell 
identity. Super-enhancers are enriched for disease-associated SNPs, particularly when the 
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super-enhancers were defined in disease-relevant cell types. In cancer cells, super-enhancers 
are enriched at genes with known oncogenic function.  
Some associations between YAP/TAZ and proteins of the so-called “enhanceosome”, a 
nucleoprotein complex that assembles at enhancers and connects transcriptional activators 
with the transcriptional machinery, have been recently reported. For example, YAP/TAZ 
interact with Med1, and they are functionally linked to p300 and CDK9. However, the nuclear 
mechanism of YAP/TAZ activity at enhancers remains poorly understood. 
Super-enhancers in tumour cells are strongly enriched for binding of BRD4. BRD4 is a 
chromatin reader that positively regulates transcription by binding acetylated histones and 
core components of the transcriptional apparatus. BRD4 interacts directly with the Mediator 
complex, linking transcription factors with RNA PolII complex, and it facilitates of 
recruitment of the positive transcription elongation factor (PTEFb) to paused RNA PolII, 
allowing transcriptional elongation (Chiang, 2009). Given the important roles of both BRD4 
and YAP/TAZ on the enhancers of cancer cells, we decided to investigate whether a 
functional interaction could exist between YAP/TAZ/TEAD and BRD4. We decided to focus 
on BRD4 also in light of the the availability of drugs targeting BET-proteins, which might be 
used to inhibit YAP/TAZ nuclear activity in cancer cells.  
 
 
YAP/TAZ/TEAD interact with BRD4  
 
We speculated that, if BRD4 has a role in activating the transcription of YAP/TAZ target 
genes, this must entail a contact between BRD4 itself and YAP/TAZ or TEAD. 
To verify our hypothesis, we performed co-immunoprecipitation (IP) assays in nuclear 
extracts of MDA-MB-231 cells with anti-BRD4 antibody (we used pre-immune IgGs as 
negative control). We found that endogenous BRD4 associated with endogenous YAP and 
TEAD1. In a reciprocal experiment, we performed IP with anti-YAP antibody and we could 
detect BRD4 (along with TEAD1) in YAP immunocomplexes (Figure 12A). 
To confirm in vivo the previously detected biochemical interactions, we performed Proximity 
Ligation Assay (PLA) in MDA-MB-231 cells. This immunofluorescence-based technique 
allows the visualization of endogenous protein complexes in individual fixed cells, as 
fluorescent dots appear only when proteins are very close to each other (40nm) (Koos et al., 
2014). Furthermore, this assay allows to appreciate the subcellular localization of protein 
complexes. 
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MDA-MB-231 cells were seeded on fibronectin-coated glass chamber slides and fixed in 4% 
PFA before performing the proximity ligation assays with anti-BRD4 and anti-TEAD 
antibodies. As shown in figure 12B, we could detect BRD4-TEAD complexes (red dots) in 
the nuclei of MDA-MB-231 cells. As control, no dots could be detected in the nuclei when 
we performed the PLA omitting either of the primary antibodies. We couldn’t find a good 
BRD4 primary antibody raised in mouse to be combined with our best performing YAP and 
TAZ antibodies produced in rabbit. 
To better characterize the relationship between YAP/TAZ/TEAD and BRD4 proteins, we 
studied protein-protein interactions via biochemical analysis with purified, isolated proteins. 
First, we overexpressed HA-BRD4 in HEK293T cells and we used anti-HA antibodies to 
immobilize it on protein A-agarose beads. Then, we incubated this HA-BRD4-loaded resin 
with FLAG-tagged YAP, TAZ, or TEAD1 isolated from HEK293T protein extracts. After 
extensive washing, we checked by immunoblot which proteins had been capture by HA-
BRD4. As shown in Figure 12C, FLAG-TEAD1 was efficiently captured by the HA-BRD4-
loaded resin. FLAG-YAP interacted with HA-BRD4 only in the presence of FLAG-TEAD1, 
whereas FLAG-TAZ showed a tiny interaction with BRD4 and a stronger binding in the 
presence of FLAG-TEAD1. These data suggest that TEAD have a prominent role in 
stabilizing (if not mediating) the interaction between YAP/TAZ and BRD4. 
Next, we immobilized HA-YAP on agarose beads and we incubated the HA-YAP-loaded 
resin with isolated FLAG-TEAD and FLAG-BRD4. BRD4 could be captured by HA-YAP 
only in the presence of FLAG-TEAD1, reinforcing the conclusion of the previous experiment 
(Figure 12D). 
Overall, these data indicate that the transcriptional coactivator BRD4 can physically interact 
with YAP/TAZ/TEAD in the nucleus of MDA-MB-231 cells; within the complex, there is a 
direct interaction between BRD4 and TEAD, which serves to stabilize the YAP/TAZ-BRD4 
interaction. 
 
 
BRD4 binds the cis-regulatory elements of YAP/TAZ/TEAD target genes 
 
We then wanted to assess if BRD4 occupies the cis-regulatory regions of YAP/TAZ target 
genes. 
First of all, we performed chromatin immunoprecipitation with anti-BRD4 antibody followed 
by qPCR (ChIP-qPCR) in control and BRD4-depleted MDA-MB-231 cells, to verify the 
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specificity of the antibody. As a negative control, we performed the immunoprecipitation with 
pre-immune immunoglobulins to measure background signal. As shown in figure 13A, DNA 
regions enriched by BRD4 ChIP in control cells are not enriched in cells transfected with 
BRD4 siRNA, confirming the reliability of BRD4 antibody for ChIP. 
We next verified that BRD4 could co-occupy chromatin with YAP/TAZ. Indeed, the 
sequences of a sample of YAP/TAZ-occupied enhancers were enriched in BRD4 ChIP, as 
well as their target promoters (even if the TSSs did not display YAP/TAZ binding sites) 
(Figure 13B). 
At the time of writing this thesis, we just performed ChIP-seq experiments for BRD4, to 
assess the overlap between YAP/TAZ/TEAD and BRD4 binding sites genome-wide. Data 
analysis is currently in progress. However, preliminary visual inspection of some loci 
confirmed the results of ChIP-pPCR experiments described above. 
 
 
Inhibition of BRD4 impairs the expression of YAP/TAZ/TEAD target genes. 
 
Data presented so far prove that YAP/TAZ/TEAD can interact with BRD4 on chromatin in 
MDA-MB-231 cells. What are the functional implications of this interaction? To answer this 
question, we decided to investigate the effect of BRD inhibition at the genome wide level by 
RNA-sequencing in MDA-MB-231 cells, and to compare it with the effect of YAP/TAZ 
silencing. 
We used two strategies to inhibit BRD. First, we knocked down BRD4 and its cognate 
proteins BRD2 and BRD3 with siRNAs; we chose to knockdown all the BRD transcripts 
because depletion of the sole BRD4 might induces compensatory effects by other BET-
proteins, thus being not effective. Second, we pharmacologically inhibited BRD4 with a small 
molecule. As previously anticipated, BRD4 is an attractive therapeutic target. To date, a large 
number of compounds that target BET family proteins have been developed, and many are 
currently under clinical evaluation for the treatment of cancer. These small-molecules, such as 
JQ1, PFI-1 and I-BET762, directly target BRD4 and other BET proteins by occupying the 
amino-terminal bromodomains and impeding their binding to acetylated lysines of histones 
and transcription factors, thus restraining BRD activity (Filippakopoulos & Knapp, 2014). 
Early clinical trials have shown promising effects on treatments with BET-inhibitors in a 
variety of malignancies (Shi & Vakoc, 2014). We selected as paradigm JQ1 (thieno-triazolo-
1, 4-diazepine), a potent and specific inhibitor of BET bromodomains.  
	   28	  
We prepared duplicate samples for each of the following experimental conditions: 
a) MDA-MB-231 cells transfected with control siRNA, or treated with DMSO (vehicle); 
b) MDA-MB-231 cells transfected with two independent combinations of YAP/TAZ 
siRNAs for 48h; 
c) MDA-MB-231 cells transfected with two independent combinations of siRNAs 
targeting BRD2-3-4 for 72h; 
d) MDA-MB-231 cells treated with 1mM JQ1 for 24h. 
Total RNA was extracted, depleted of rRNAs and analysed by sequencing. To get a general 
picture of the results, we performed unsupervised hierarchical clustering of samples, based on 
the transcripts displaying the highest variations between the various experimental conditions: 
we found that samples treated with JQ1 clustered with BRD-depleted cells, and with 
YAP/TAZ depleted cells, suggesting that YAP/TAZ depletion and BRD inhibition must have 
some overlapping effects (Figure 13C). More in detail, YAP/TAZ/TEAD-dependent 
transcription in MDA-MB-231 cells was in large part sensible to BRDs depletion or JQ1 
treatment. In particular, YAP/TAZ are required for the activation of ~2100 genes; 68% of 
these genes were downregulated after JQ1 treatment (Figure 13D), and most of these genes 
(~930) were also downregulated by BRD depletion with both combinations of siRNAs. 
Although JQ1 has, as expected, a wider effect compared to YAP/TAZ depletion (inducing the 
downregulation of ~3000 genes), our data suggest that it can inhibit the expression of a large 
fraction of the YAP/TAZ transcriptional targets in MDA–MB-231, and that YAP/TAZ target 
genes are more likely to be sensitive to JQ1 treatment compared with non YAP/TAZ targets 
(Chi-square test with Yates correction, p < 0.0001). We plan to complement this analysis 
which ChIP-seq results, to assess to which extent this positive correlation between YAP/TAZ 
activity and sensitivity to JQ1 can be attributed to the joint control of the promoter by BRD4 
and YAP/TAZ.  
 
 
BRD4 is instrumental for YAP/TAZ biological activity 
 
We then wanted to assess whether BRD inhibition could block YAP/TAZ biological activity. 
As readout, we evaluated transforming capacity, as measured by colony formation in soft 
agar, a clonal assay in anchorage-independent growth conditions, used to test cell 
transformation and aberrant growth.  
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First, we examined colony formation after knockdown of BRD4 in MDA-MB-231 cells, 
whose ability to form colonies in soft agar depends on YAP/TAZ. For this, we transduced 
MDA-MB-231 cells with lentiviruses carrying doxycycline inducible shRNAs (shCO, 
shBRD4#1 or shBRD4#2). By immunoblotting, we validated the efficiency of shRNAs for 
BRD4 in MDA-MB-231 cells. Both BRD4 shRNAs were able to reduce BRD4 protein levels 
upon shRNAs expression by doxycycline treatment for 5 days (Figure 14A). Cells were 
seeded into soft agar in the absence or presence of doxycycline and allowed to grow for 3 
weeks; subsequently, cells were fixed and the number of colonies was recorded. BRD4 
knockdown reduced the number of colonies formed by MDA-MB-231 cells (Figure 14B). 
Next, we tested if BRD4 is instrumental for YAP/TAZ activity during transformation in 
another system. For this, we transduced immortalized non-tumorigenic mammary epithelial 
cells (MCF10A) with vectors encoding for an activated version of YAP (YAP5SA, lacking all 
LATS phosphorylation sites causing increased YAP nuclear localization). Control cells 
(empty-vector-transduced) were not able to form colonies in soft agar, whereas YAP 
overexpression conferred MCF10A cells the capacity to seed colonies with high efficiency. 
YAP5SA-overexpressing cells were transduced with lentiviral vectors carrying inducible 
shRNAs (shCO, shBRD4#1 or shBRD4#2; see figure 14C for knockdown efficiency); 
combined expression of YAP5SA and BRD4 shRNAs strongly reduced colony formation 
compared to cells expressing both YAP5SA and shCO (Figure 14D). Summing up, BRD4 is 
required for YAP-dependent transformation of mammary epithelial cells. 
Prompted by these results, we next asked whether we could achieve inhibition of YAP 
oncogenic function by pharmacological inhibition of BRD4 with JQ1. Consistently with the 
results obtained with BRD4 shRNAs, treatment with JQ1 blunted or even abolished the 
growth of colonies in soft-agar from both MDA-MB-231 cells and YAP-overexpressing 
MCF10A cells in a dose-dependent manner (Figure 14E,F). 
Next, we asked if JQ1 affected colony progression, beyond colony initiation. For this, we 
performed soft agar assays with MCF10A-YAP cells and started JQ1 treatment at different 
time points (at the moment of seeding, or 7 or 15 days later). Starting the treatment 7 or 15 
days after seeding, fewer cells grew enough to form sizable colonies, thus confirming that 
JQ1 impaired the growth of already established colonies (Figure 14G). In conclusion, 
YAP/TAZ require BRD4 to mediate oncogenic cell growth in vitro, and treatment with JQ1 
led to significant inhibition of YAP/TAZ-dependent proliferation, phenocopying BRD4 
knockdown. 
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JQ1 does not affect BRD4-TEAD interaction or YAP/TAZ recruitment on enhancers 
 
Results described so far delineate a model whereby a physical interaction between 
YAP/TAZ/TEAD and BRD4 on chromatin mediates the activation of YAP/TAZ target genes 
and YAP/TAZ biological activity in breast cancer cells; inhibition of BRD4 with JQ1 blocks 
these events.  
We have performed some experiments to investigate how JQ1 impairs the activity of the 
YAP/TAZ/TEAD/BRD4 complex.  
As shown in figure 12, BRD4 could directly interact with TEAD1 and this interaction 
stabilized BRD4 association with YAP and TAZ, too. We found that JQ1 does not interfere 
with these interactions. HA-BRD4 immobilized on agarose beads was able to capture FLAG-
TEAD1 also in the presence of JQ1 in the reaction buffer (Figure 15A).  
In cell extracts of MDA-MB-231 cells treated with 1 mM JQ1 for 6h (a time sufficient to 
detach BRD4 from chromatin, see below), TEAD1 and YAP co-precipitated with BRD4 also 
in the presence of JQ1. A different compound targeting the bromodomain (PFI-1) had the 
same inconsequential effect as JQ1 (Figure 15B). These results exclude that JQ1 directly 
changes the affinity between BRD4 and TEAD1 (and YAP).  
JQ1 competes with acetylated histone tails to bind the bromodomain of BET-proteins, 
resulting in BRD4 release from chromatin. We reasoned that JQ1 (while not affecting the 
capacity of BRD4 to interact with TEAD and YAP/TAZ per se), might lead to the detachment 
of the whole complex from chromatin.  
Thus, we performed ChIP-qPCR experiments with anti-YAP/TAZ antibodies in MDA-MB-
231 cells treated with 1 mM JQ1 for 6h. Contrary to our hypothesis, YAP/TAZ bound their 
cis-regulatory regions with the same strength both in DMSO and in JQ1-treated cells (Figure 
15C). Instead, BRD4 binding to the same loci was reduced in the presence of JQ1 (Figure 
15D). These results suggest that JQ1 does not affect YAP/TAZ capacity to remain bound on 
chromatin. 
 
 
Loss of BRD4 impairs Pol II recruitment on YAP/TAZ/TEAD-regulated genes 
 
Our evidence indicates that BRD4 has an essential role in mediating YAP/TAZ/TEAD 
transcriptional and biological activities in breast cancer cells and that BRD4 acts after 
YAP/TAZ recruitment to chromatin.  
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BRD4 interacts with Mediator complex, linking transcription factors with RNA-polymerase II 
(Pol II). In particular, BRD4 recruits PTEF-b (positive transcriptional elongation factor b), 
which contains a kinase (CDK9) that phosphorylates Pol II on its carboxy terminal domain 
(CTD), activating transcriptional elongation by releasing Pol II promoter pausing.  
Thus, we compared the phosphorylation state of Pol II in MDA-MB-231 cells by 
immunoblotting upon depletion of BRDs or YAP/TAZ by siRNAs, or JQ1 treatment. The 
level of Pol II protein was the same in all the different conditions, but the phosphorylation of 
Pol II on Ser2 (the target of CDK9) was reduced (Figure 16A). Thus, active elongation is 
impaired in YAP/TAZ depleted cells, as well as after BRD inhibition.  
We reasoned that defective elongation might be explained either by the specific inhibition of 
elongation, or by a reduced recruitment of Pol II on transcription start sites (TSS). To 
discriminate between these two possibilities, we performed ChIP-qPCR experiments with 
anti-Pol II antibody (and with pre-immune immunoglobulins as negative control) in MDA-
MB-231 cells, upon transfection with siBRDs, siYAP/TAZ or treatment with JQ1. We 
investigated the recruitment of Pol II on the TSS of genes regulated by YAP/TAZ from 
enhancers, that we know to be regulated by YAP/TAZ and BRD from our RNA-seq analysis. 
We found that Pol II loading on the promoters of YAP/TAZ target genes is specifically 
reduced upon depletion of YAP/TAZ or BRDs or JQ1 treatment, compared to control cells 
(Figure 16B). Instead, Pol II recruitment to GAPDH promoter (representing a non-YAP/TAZ 
target) was either not affected or even increased in the case of JQ1, suggesting a specific 
effect on YAP/TAZ target genes, rather than a general/aspecific reduction of Pol II 
recruitment to TSSs.  
In conclusion, our results pointed to recruitment of Pol II as the crucial step downstream 
YAP/TAZ/TEAD and BRD4 interaction. 
 
 
 
 
 
 
 
 
 
 
	   32	  
DISCUSSION 
 
YAP/TAZ bind distal enhancers to activate a cell-growth transcriptional program 
The work here presented focuses on YAP/TAZ nuclear function as regulators of gene 
expression. YAP/TAZ have fundamental roles in important biological processes and much 
effort has been dedicated to the study of their function in embryonic development, normal 
tissue homeostasis and cancer, and to the investigation of the mechanisms that regulate 
YAP/TAZ nuclear availability. Instead, how YAP/TAZ work in DNA the nucleus (the genetic 
program they activate, the way they interact with chromatin, their co-factors) have received 
less attention. Most of our knowledge was based on few paradigmatic target genes (such as 
the regulation of CTGF), but systematic studies were missing.  
In this thesis, we performed an unbiased study of YAP/TAZ transcriptional activity, by 
carrying out genome-wide analyses of YAP/TAZ binding sites in breast cancer cells through 
ChIP-seq, coupled to transcriptomic profiling. Our analysis revealed that the vast majority 
(91%) of YAP/TAZ-bound cis-regulatory regions coincides with enhancer elements, located 
distant from transcription start sites (TSS). The only previous genome-wide analysis of YAP 
binding sites used DNA microarrays to identify ChIP’d DNA (ChIP on chip), and the array 
only contained promoter sequences; thus, it actually could detect only a fraction of YAP 
binding sites (B. Zhao et al., 2008). Our discovery that YAP/TAZ binding to enhancers was 
confirmed by other groups in different tumour types (Galli et al., 2015; Stein et al., 2015), 
strongly suggesting that binding to distal regulatory regions is the preferred modality of gene 
regulation by YAP/TAZ, at least in cancer cells.  
 
Recent studies reported that enhancer usage is altered in cancer cells in comparison with their 
normal counterparts (Pott & Lieb, 2015). We speculate that YAP/TAZ aberrant activation in 
cancer might have a role in the reshuffling of enhancer usage in tumor cells. 
 
As we aimed at defining YAP/TAZ transcriptional program in MDA-MB-231 cells, we had to 
deal with the task of matching YAP/TAZ-occupied enhancers with the genes they regulate. 
Most strategies to assign a TF binding site to its target gene are based on proximity, that is, it 
is assumed that the target promoter is the closest one in the linear DNA sequence. However, 
genomes are known to be organized in 3D structures, whereby distant enhancers are in 
physical contact with regulated promoters by chromatin looping. Recently, Jin et al. defined a 
map of enhancer-promoter contacts in human fibroblasts by Hi-C. We used this map to 
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associate distal YAP/TAZ-binding sites with regulated promoters, discovering a wide list of 
new YAP/TAZ direct target genes. By gene ontology analysis, we identified the regulation of 
cell proliferation as the main biological process in which are involved YAP/TAZ direct target 
genes. In fact, most YAP/TAZ effectors are proteins directly involved in specific steps of the 
cell cycle, such as assembly of the licensing complex, DNA replication and repair, 
chromosome segregation and cytokinesis. These are critical and common elements in most 
YAP/TAZ-dependent biological events, such as organ growth and tissue regeneration, that 
can hardly be explained by sporadic set of YAP/TAZ downstream targets discovered so far in 
mammalian cells. Instead, we show that the growth-controlling transcriptional program of 
YAP/TAZ is vast and redundant and includes other transcription factors, that might propagate 
YAP/TAZ message. MYC is one example. We exploited MYC as a paradigm to verify that 
transcription is directly controlled in breast cancer cells by YAP/TAZ-bound enhancers 
through chromatin looping. Functionally, MYC is a relevant, albeit only partial YAP/TAZ 
effector.  
 
YAP/TAZ associate with TEAD transcription factors genome-wide 
YAP/TAZ indirectly bind DNA through other transcription factors. A number of DNA-
binding platforms have been reported for YAP/TAZ, including TEAD1-4, RUNX, p73, 
TBX5, and others. Most of these studies have been based on few targets or reporters, but a 
genome-wide view of the determinants that recruit YAP/TAZ to the chromatin was lacking. 
Our genome-wide data revealed that TEAD proteins are the major platform through which 
YAP/TAZ bind DNA in breast cancer cells. 75% of YAP/TAZ ChIP-seq peaks contain a 
TEAD motif that often occupies the summit of YAP/TAZ peak, i.e. the point where the 
immunoprecipitated protein sit. By carrying out a TEAD4 ChIP-seq, we confirmed that 78% 
of YAP/TAZ binding sites are indeed shared by TEAD. TEADs are required to recruit 
YAP/TAZ to chromatin and they are essential for YAP/TAZ transcriptional functions, 
supporting the view that TEADs determine where YAP/TAZ bind DNA to regulate 
transcription. Thus, even though a plethora of potential partners exist, our data indicate that 
YAP/TAZ mainly cooperate with TEAD proteins in MDA-MB-231 cells. In fact, by 
comparison, of the various transcription factors proposed to work as YAP/TAZ DNA-binding 
platforms, only RUNX1/2 motif is observed in YAP/TAZ peaks on MDA-MB-231 cells. 
However, RUNX1/2 is not preferentially enriched close to the summit of the YAP/TAZ peaks 
and thus it is unlikely that YAP/TAZ bind RUNX1/2 to attach to DNA.   
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YAP/TAZ interact with the transcriptional regulator BRD4 
How do YAP/TAZ activate transcription? What connects them with the RNA polymerase 
complex? 
The finding that YAP/TAZ occupy enhancers suggested us to focus on BRD4. BRD4 was 
found to regulate the expression of oncogenic drivers through occupying super-enhancers in 
multiple myeloma cells and other tumors (Lovén et al., 2013), nicely paralleling YAP/TAZ 
oncogenic transcriptional activity (Galli et al., 2015). 
BRD4 was originally identified as a mitotic chromosome binding protein that remains 
associated with acetylated chromatin throughout the entire cell cycle providing an epigenetic 
memory (mitotic bookmark) (Zhao, Nakamura, Fu, et al., 2011). BRD4 also participates in 
transcription: first, it acts as a scaffold, recognizing active DNA sites and recruiting 
transcriptional apparatus through Mediator complex and PTEFb elongation factor; second, 
BRD4 shows a kinase activity, which phosphorylates C-terminal domain (CTD) of the Pol II. 
Recently, it was demonstrated that BRD4 is also a histone acetyltransferase (HAT) that evicts 
nucleosome from chromatin (Devaiah et al., 2016).  
BRD4 is essential for mouse embryonic development: Brd4 full knockout results in early 
embryonic lethality, and heterozygosity for Brd4 leads to pre- and postnatal growth defects 
that are associated with reduced proliferation in vitro and in vivo (Houzelstein et al., 2002). 
These data support the essential role of BRD4 in normal cells.  
In cancer, BRD4 represents a non-oncogenic addiction: it is not an oncogene (unless when 
fused with NUT in the very rare and aggressive midline carcinoma), but its function is 
required for cancer cell survival. Indeed, BRD4 is an attractive therapeutic target and several 
drugs targeting BET-proteins are available (Filippakopoulos & Knapp, 2014). Some of the 
chemical compounds targeting BRD4 are currently under pre-clinical or clinical evaluations 
for the treatment of cancer and show promising effects in a variety of malignancies (Shi & 
Vakoc, 2014). That said, not all tumor cells are equally sensitive to BET-inhibitors, and it is 
still unclear what determines therapy efficacy or failure. 
Prompted by the prominent role of both YAP/TAZ and BRD4 on enhancers in cancer cells, 
we postulated that they might indeed work together. Actually, we demonstrated that BRD4 
could form a complex with YAP/TAZ through direct binding with TEAD proteins in the 
nucleus of breast cancer cells, connecting YAP/TAZ with the basal transcriptional machinery. 
By ChIP experiments, we observed that BRD4 could occupy enhancers and promoter regions 
of YAP/TAZ target genes. Thus, we speculated that BRD4 is necessary to relay YAP/TAZ 
transactivating signal to target genes.  
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BET inhibitors block YAP/TAZ transcriptional and biological activity 
In the first part of our project, we discovered that YAP/TAZ regulate a complex 
transcriptional program mediating their biological functions. Notably, both BRD4 depletion 
and JQ1 treatment led to significant inhibition of YAP/TAZ-dependent cell transformation 
and aberrant growth in vitro. Overall, YAP/TAZ/TEAD and BRD4 interactions resulted 
essential for YAP/TAZ biological activity in vitro. Transcriptome analysis by RNA-seq 
suggested that YAP/TAZ/TEAD-dependent transcription in breast cancer cells was in large 
part sensible to BRD proteins depletion or JQ1 treatment. BRD4 is a general regulator of 
transcription, thus we reasoned that the above transcriptional effects on MDA-MB-231 cells 
of BRDs knockdown, as well as the pharmacological inhibition that we observed, might be 
the result of a global inhibition of transcription. We observed that JQ1 treatment inhibited and 
activated the expression of similar number of transcripts, suggesting that it does not act as an 
aspecific inhibitor of transcription; instead, it seems to induce specific changes in the cellular 
transcriptional program mediated by YAP/TAZ. 
How does JQ1 impair the activity of the YAP/TAZ/TEAD/BRD4 complex? We excluded that 
JQ1 inhibitor directly changes the affinity between BRD4 and TEAD1 (and YAP), nor it 
affects YAP/TAZ capacity to remain bound on chromatin. More studies will be required to 
decipher the molecular mechanism of the interaction between YAP/TAZ/TEAD and BRD4, 
and how it’s affected by JQ1. At the end of this cascade, BRD proteins mediate the 
recruitment of Pol II to the TSSs of YAP/TAZ target genes, as demonstrated by Pol II ChIP-
qPCR experiments. 
In conclusion, we have identified BRD4 (a general transcriptional regulator) as a functional 
partner of YAP/TAZ/TEAD, revealing a new aspect of YAP/TAZ activity as transcriptional 
co-activators on enhancers. Conversely, we wish that the follow-up of this study will shed 
new light on BRD4 activity in cancer cells. 
The underlying molecular mechanism of BRD4 activity in cancer is poorly understood. In 
agreement with our transcriptomic data, studies with BET inhibitors indicate that not all genes 
are equally affected by JQ1, but instead transcription is disproportionately suppressed at 
specific sites. Little is known about how the gene-specific activity of BRD4 is determined 
(Wu et al., 2013). BRD4 lacks specific DNA binding motif. Our data rise the possibility that 
BRD4 and its associated transcriptional complex are recruited to gene-specific 
promoters/enhancers by YAP/TAZ in cancer. 
In the long run, we wish to establish a functional link between the addiction to YAP/TAZ that 
some cancer cells display, and responsiveness to drugs targeting BET proteins. If this link 
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indeed exists, it might provide the rationale to use YAP/TAZ activation (which can be 
diagnosed in tumor biopsy by IHC for YAP/TAZ themselves, or by gene expression 
profiling) as a predictive marker for response to BET-inhibitors.  
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MATERIALS AND METHODS 
 
The methods here listed are part of the Piccolo’s Lab protocol book and thus presented with 
minor modifications, if any, in respect to published material or other thesis works published 
by our Lab. 
 
Reagents and Plasmids 
pCS2-FLAG-mTAZ, pCDNA-HA-YAP, pCDNA-FLAG-YAP and pBABE-hygro-FLAG-
mTAZ wild-type were previously described (Zanconato et al., 2015). FLAG-mTAZ S51A 
was generated by PCR from pCS2 FLAG mTAZ wild-type (Dupont et al., 2011) and 
subcloned in pBABE-hygro. pBABE-puro-hYAP wild-type was obtained subcloning FLAG-
hYAP1 wild-type siRNA insensitive (pCDNA3-FLAG-hYAP1 wild-type siRNA insensitive) 
in the retroviral vector. FLAG-hYAPS94A was generated by PCR from pCDNA3-FLAG-
hYAP wild-type (Aragona et al., 2013) and subcloned in pBABE retroviral plasmid (pBABE-
puro) to establish stable cell-lines. pBABE-hygro (#1765) and pBABE-puro (#1764) empty 
retroviral vectors were purchased from Addgene. pCMV6-FLAG-MYC-TEAD1 was from 
Origene. 
FU-tet-o-hc-myc (#19775, Maherali et al., 2008) and FUdeltaGW-rtTA (#19780, Maherali 
et al., 2008) were purchased from Addgene. FU-tet-o-EGFP-ires-PURO was described in 
Cordenonsi et al., 2011. pCMV2-FLAG-BRD4  was from Addgene (#22304). pCS2 HA-
BRD4 was generated by PCR from pCMV2-FLAG-BRD4 and subcloned in pCS2+ plasmid. 
Annealed oligos for shRNAs (shCO –mNF2-, shBRD4#1, shBRD4 #2, listed in TABLE 3) 
were cloned into TetON pLKO.puro from Addgene (#21915). 
All constructs were confirmed by sequencing. 
Doxycycline and PFI-1 were from Sigma Aldrich; JQ1 was from BPS Bioscience (#27402). 
 
Cell culture conditions 
MDA-MB-231 cells were from ICLC. MDA-MB-231 cells were authenticated by DNA 
profiling of highly polymorphic STR loci. MDA-MB-231 cells were cultured in DMEM/F12 
(Life Technologies) supplemented with 10% FBS (foetal bovine serum), 1% (2mM) 
glutamine and 1% antibiotics. After infection with doxycycline-inducible vectors, MDA-MB-
231 cells were maintained in media supplemented with Tet-approved FBS (Clontech), to 
reduce background expression of the transgene in the absence of doxycycline.  
MCF10A cells were from ATCC. MCF10A cells were cultured in DMEM/F12 (Life 
Technologies) with 5% HS (horse serum), 1% glutamine and 1% antibiotics, freshly 
supplemented with insulin, EGF, hydrocortisone, and cholera toxin. HEK293T and 293GP 
cells (packaging cell lines for viral particles production) were cultured in DMEM (Life 
Technologies) supplemented with 10% FBS, 1% glutamine and 1% antibiotics. 
 
siRNA transfection 
siRNA transfection was performed using Lipofectamine® RNAiMAX (Life technologies) in 
antibiotics-free medium (Opti-MEM® Medium). Cells were seeded in a 6-well plate to be 30-
40% confluent at transfection. For each transfection, 100 pmol of siRNA were diluted in 250 
µl of Opti-MEM® medium and subsequently added to 5 µl of Lipofectamine® RNAiMAX 
Reagent diluted in 250 µl of Opti-MEM® medium. This mix was incubated for 15 minutes at 
room temperature and added to the cells. siRNA sequences are in TABLE 3. Cells were 
harvested 48h after transfection, unless differently specified. 
 
DNA transfection  
DNA transfections were performed with TransitLT1 (Mirus Bio). LT1 reagent and serum free 
medium (Opti-MEM® Medium) were mixed and incubated 5 minutes; then we added plasmid 
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DNA to previous mix, incubating other 15 minutes. Finally, the transfection mix is 
homogeneously distributed on cells. 
Total RNA extraction and cDNA synthesis 
RNA was purified using RNeasy mini kit (Qiagen; 74106). Cells were harvested in Buffer 
RLT supplemented with 40mM dithiothreitol. Lysates were mixed with one volume of 70% 
ethanol, transferred to RNeasy Mini spin columns and centrifuged for 30 seconds. The 
column was washed with RW1 Buffer, and then incubated for 15 minutes at room 
temperature with DNaseI in RDD Buffer to minimize contamination of the extracts with 
cellular DNA. A wash with RW1 Buffer and other two washes with RPE Buffer were 
necessary to improve RNA yield and purity. RNA was eluted in 30-50µL of RNase-free water 
by centrifuging columns for 1 minute. Total RNA was quantified using the NanoDrop ND- 
1000 Spectrophotometer (NanoDrop Technologies Inc.).  
1ug of total RNA was heated for 5 minutes at 70°C and left on ice for 1 minute to denature 
possible secondary structures that could interfere with the retrotranscription process. Then, 
retrotranscription reaction mix was added; the mix contains FS buffer, 0,01M DTT, 2 mM 
dNTPs mix, 25 ng of oligo-dT , 100U Mo-MLV Reverse Transcriptase (Life Technologies; 
28025-013), 40U RNaseOUT (Life Technologies; 10777-019) and RNase-free water 
(Ambion) up to 11 µL. Retrotranscription was carried out for 1hour and half at 37°C. The 
reaction was then inactivated at 70°C for 10 minutes and samples were prepared for qRT-
PCR  
 
Quantitative Real-Time PCR (qRT-PCR) 
Quantitative real-time PCR (qPCR) analyses were carried out on retrotranscribed cDNAs with 
Rotor-Gene Q (Quiagen) thermal cycler. Every amplification reaction contained: 5 µL of 
diluted cDNA, 0.75 µL of forward and reverse primers (0.5 µM each), and FastStart SYBR 
Green Master (Roche) in 15 µL. Amplification was carried out as follows: 10 seconds at 95 
°C, 15 seconds at 60 °C, 20 seconds at 72 °C for 40 cycles. Each sample was run in triplicate; 
expression values of test genes were normalized to GAPDH expression.  
Primer sequences are listed in (TABLE 4).  
For gene expression analysis with TaqMan Arrays cDNA was synthesized with High 
Capacity RNA-to-cDNA Kit (Invitrogen). Target genes were then quantified with custom 
TaqMan Low Density Arrays on a 7900HT Fast Real-Time PCR System (Applied 
Biosystems), using TaqMan Universal PCR Master Mix (Applied Biosystems). TaqMan 
assays included in the array are listed in TABLE 6. Expression levels are normalized to 
GAPDH. 
 
RNA sequencing 
For total RNA extraction RNeasy Mini Kit (QIAGEN) was used, and contaminant DNA was 
removed with RNase-Free DNase (QIAGEN). Libraries for deep-sequencing were prepared 
with the Illumina TruSeq Standard Total RNA with Ribo-Zero GOLD kit, and sequencing 
was performed with Illumina HiSeq2500. About 20M reads/sample were obtained. Reads 
were aligned to the human genome (GRCh37/hg19) with TopHat2; expression levels and 
differentially expressed genes were determined with HTseq and edgeR. 
 
ImmunoBlot analysis 
Whole cell lysates were obtained by sonication in lysis buffer (20 mM HEPES [pH 7.8], 100 
mM NaCl, 5% glycerol, 5 mM EDTA, 0.5% Np40, and protease and phosphatase inhibitors) 
with a water bath cell disruptor (Diagenode Bioruptor). The lysate was centrifuged 10 
minutes at 4 °C to eliminate the insoluble fraction. Total protein concentration of lysates was 
measured by Bradford quantitation, staining proteins with Coomassie Blue G250 and 
measuring the absorbance of the solution at 595 nm (a calibration curve was prepared with 
	   39	  
increasing BSA amounts). Protein extracts were boiled 3 minutes at 95 °C in 1X FSB (50mM 
Tris-HCl, pH 6.8; 2% SDS; 0.1% bromophenol blue; 10% glycerol; 2% 2-mercaptoethanol).  
Equal amounts of protein were separated by SDS-PAGE in commercial 4-12% or 10% 
Nupage MOPS acrylamide gels (Invitrogen) and transferred onto PVDF membranes 
(ImmobilonP) by wet electrophoretic transfer (50 mM Tris; 40 mM Glycine; 20% methanol; 
0.04% SDS). In general, blots were blocked one hour at RT with 0,5% non-fat dry milk 
(BioRad) in TBSt (0,05% Tween) and incubated o.n. at 4°C with primary antibodies (listed in 
TABLE 2). Horseradish peroxidase-conjugated secondary antibodies were incubated 1 hour at 
RT. Blots were developed with Pico or Dura SuperSignal West chemiluminescent reagents 
(Pierce). Chemiluminescence was digitally acquired with ImageQuant LAS 4000. 
  
Immunoprecipitation 
For immunoprecipitation experiments from whole cell lysates, cells were lysed by sonication 
lysis buffer (20 mM HEPES pH 7.8, 400 mM KCl, 10% Glycerol, 5 mM EDTA, 0.4% NP40), 
freshly supplemented with 1 mM DTT, and protease and phosphatase inhibitor cocktails and 
cleared by centrifugation. Before immunoprecipitation, extracts were diluted to 20 mM 
HEPES (pH 7.8), 100 mM NaCl, 5% Glycerol, 2.5 mM MgCl2, 1% TritonX100 and 0.5% 
NP40 and incubated O/N at 4°C with specific primary antibody or IgG (listed in TABLE 2). 
Protein A or G-magnetic beads (from Invitrogen) were incubated O/N at 4°C in PBS with 2% 
BSA and 0.05% CHAPS. Next, immunoprecipitation preps were incubated with magnetic 
beads at 4 °C for 2 hours. Immunocomplexes were then washed with cold binding buffer four 
times, resuspended in SDS sample buffer, and subjected to SDS-PAGE and Immuno blot 
analysis. For overexpressed proteins, HEK293T cells were firstly transfected with 80 ng/cm2 
of relative plasmid; DNA amount was adjusted to 160 ng/cm2 with pBluescript. 
For immunoprecipitation of endogenous nuclear proteins, we performed nuclear protein 
extraction. MDA-MB-231 cytoplasmic membranes were first lysed by hypotonic buffer 
(20mM HEPES, 20% Glycerol, 10mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.1% NP40). 
Nuclei were then obtained by centrifugation and lysed with hypertonic buffer (hypotonic 
buffer, 500mM NaCl).  Extracts were diluted to 140mM NaCl. Next, samples are processed 
as above. 
For immuniprecipitation from purified proteins, HA-tagged protein (BRD4 or YAP) was 
overexpressed in HEK293T cells; anti-HA antibody was used to immobilize HA-tagged 
protein on protein A-agarose beads. HA-resin was incubated with FLAG-tagged proteins, 
isolated from HEK293T protein extracts, at 4C O/N. Immunocomplexes were then washed 
with binding buffer. 
Where indicated, cells were treated for 24h with chemical compounds, contained also in 
buffers for immunoprecipitation. 
 
In situ proximity ligation assay (PLA) 
In situ PLA was performed with DuoLink In Situ Reagents from Olink Bioscience (Sigma). 
MDA-MB-231 cells seeded in fibronectin-coated glass chamber and fixed slides 24h later in 
4% PFA for 10 min at RT. Proximity ligation assays were performed as indicated by the 
provider's protocol, after an overnight incubation with primary antibodies (listed in TABLE 2) 
following the immunofluorescence protocol: slides were permeabilized 10 min at RT with 
PBS 0.3% Triton X-100, and blocking in 10% Goat Serum (GS) in PBST for 1 hr followed by 
incubation with primary antibody (diluted in 2% GS in PBST) for 16 hr at 4 C. Images were 
acquired with Leica SP5 confocal microscope equipped with a CDD camera; for each field, a 
Z-stack was acquired; images were processed using Volocity software (PerkinElmer).  
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Growth Assay 
For growth assays, cells were seeded in 96-well plates (4000 cells/well) and fixed daily (or at 
the time points indicated in figures), starting 18h after seeding, to verify that a similar number 
of cells was present in all experimental conditions at the beginning of the time course. siRNA 
transfection was performed in cell culture dishes for 6h before seeding cells in 96-well plates. 
Doxycycline was added at the time of transfection, if required. For fixation and staining, wells 
were washed once with PBS and cells were incubated with a crystal violet solution (0.05% 
w/v Crystal violet, 1% formaldehyde, 1% methanol in PBS) for 20 min at room temperature; 
stained cells were washed with water until a clear background was visible, and air-dried. 
Crystal violet was extracted with 1% SDS (w/v in ddH2O, 100 mL/well) and absorbance at 
l=595 nm was measured with an Infinite F200PRO plate reader (TECAN). 8 replicates were 
analysed for each sample; data are presented as mean + SD. 
 
Cell cycle analysis 
To determine the fraction of cells in each phase of the cell cycle, subconfluent cells were 
trypsinized 48 hours after siRNA transfection, washed with PBS and fixed in cold 70% 
ethanol at -20 °C for at least one hour. Doxycycline was added at the time of transfection, if 
required. Fixed cells were washed in PBS and incubated in PBS containing Triton 0.1%, 20 
µg/ml Propidium Iodide and 0.2 mg/ml RNaseA for 20 minutes at room temperature. Stained 
cells were analyzed on a FC500 cytofluorimeter (Beckman Coulter).  
 
Soft agar assay 
For soft agar assay, 104 MCF10A cells/well and 3*104 MDA-MB-231 cells/well in complete 
growth medium with 0.35% agar were layered onto 0.5% agar beds in six-well plates. 
Complete medium was added on top of cells and was replaced with fresh medium twice a 
week for 15-21 days. Complete medium contained also treatments as indicated. Colonies 
larger than threshold of diameter were counted as positive for growth. Thresholds were 
arbitrary set to classify colonies according to their size. 
 
Generation of Retroviral and Lentiviral particles and infection 
To generate retroviral particles we used 293 GP cells, a packaging cell line that constitutively 
express retroviral proteins: Gag and Pol, whereas are supplied by transient transfection of an 
expression vector. These proteins are required for the correct formation of our retroviral 
particles. Our retroviral vector and the plasmid expressing Env (pmd2-Env) were all 
transfected with TransIT-LT1 (MirusBio) in 293 GP packaging cell line, previously seeded on 
a 10 cm diameter dish. Colture medium containing viral particle was collected 24-48 hours 
after transfection and filtered to discard an cellular debris. Viral surnatant was diluted with 
complete colture medium of cells to infect. Infection was performed by colturing cells with 
virus-containing medium for 24 hours. Our retroviral vectors contain an antibiotic resistance 
gene that allows us to select infected cells, by maintaining them in medium with antibiotic 
(1µg/mL of Puromycin, Higromycin). Together with infected cells transduced cells were 
cultured in the presence of antibiotic to verify the effective disappearance of not-resistant 
cells. Usually in a week all un-transduced cells should die, meaning the correct functioning of 
the selection agent and infection procedeure. 
Similar procedure has been followed for the production of lentiviral particles: lentiviral 
vectors were transfected in 293T cells in combination with Gag-Pol (psPAX2) and Env 
(pmd2-VSVG) coding plasmids. In contrast to retroviral constructs, lentiviral vectors do not 
contain any resistance gene. Recombinant lentiviral particles were harvested from the 
supernatant and used to transduce cells. 
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Chromatin immunoprecipitation (ChIP) 
Cells were seeded in 175 cm2 cell culture dishes, and transfected with siRNA if required. 
After 48 hours, 1/10 volume of fresh 11% Formaldehyde Solution (50 mM Hepes-KOH pH 
7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 11% Formaldehyde) was added to plates 
and they were swirled at room temperature for 10 minutes. Formaldehyde was quenched by 
adding 1/20 volume of 2.5 M glycine to plates for 5 minutes. Cells were washed twice with 
ice-cold PBS and harvested in PBS supplemented with protease inhibitors. Collected cells 
were centrifuged and pellets were resuspended in Lysis Buffer 1 (50 mM Hepes-KOH pH 7.5, 
10 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100) and incubated 
at 4°C for 20 minutes. Cells were centrifuged and pellets were washed in Lysis Buffer 2 (10 
mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) by gently rocking at 
room temperature for 10 minutes. After centrifugation, pellets were resuspended in Lysis 
Buffer 3 (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-
Deoxycholate, 0.5% N-lauroylsarcosine). Chromatin was sheared to 200-600bp fragments 
using a Branson Sonifier 4500D for 4 minutes (30% output, 0.4s duty cycle). Lysates were 
cleared by centrifugation. The size of fragment was checked by agarose gel electrophoresis. 
1% Triton X-100 was added to chromatin before immunoprecipitation.  
For ChIP-qPCR, ~100 µg of sheared chromatin and 3-5µg of antibody were used. For ChIPs 
of modified histones, at least 50 µg of chromatin were incubated with 2 µg of antibody. These 
mix were left rotating overnight at 4°C. Immunocomplexes were recovered with magnetic 
beads functionalized with Protein A (Dynabeads protein A from Invitrogen), blocked 
overnight in PBS + 0.5% BSA. Chromatin preps were incubated with magneti beads at 4°C 
for 2 hours. Using a magnetic stand, the beads were collected and washed twice with Wash 
Buffer Low Salt (0.1% SDS, 2 mM EDTA, 1% Triton X-100, 20 mM Tris pH 8.0, 150 mM 
NaCl) and Wash Buffer High Salt (0.1% SDS, 2 mM EDTA, 1% Triton X-100, 20 mM Tris 
pH 8.0, 500 mM NaCl). Beads were finally washed with Tris-EDTA containing 50 mM NaCl. 
The elution was performed by incubating the beads in elution buffer (Tris-EDTA + 1% SDS) 
at 65°C for 20 minutes. Beads were removed and the supernatants were incubated at 65°C 
overnight to reverse crosslink. RNA and proteins were digested by adding RNaseA (0.2 µg/ml 
final concentration) and proteinaseK (0.2 µg/ml final concentration) and incubating them at 
37°C for one hour and at 55°C for one hour, respectively. DNA was purified with 
phenol/chloroform extraction and ethanol precipitation. DNA was pelleted and washed with 
70% ethanol. Pellets were dried and resuspended in 20 uL of 10 mM Tris-HCl pH 8.0. A 
small aliquot of chromatin (2-5% of the volume used for immunoprecipitation) was saved as 
input chromatin. Input chromatin was not subjected to immunoprecipitation, but was de-
crosslinked and purified together with ChIPed samples. Quantitative real-time PCR was 
carried out with a Rotor-Gene Q (Qiagen) thermal cycler to verify the enrichment of specific 
DNA sequences; each sample was analyzed in triplicate. ChIPed DNA was diluted 1:5, input 
DNA was diluted 1:250. For each sample, triplicate PCR reactions were run with 5 uL of 
diluted DNA, 1 uM primer mix and FastStart SYBR Green Master (Roche). Amplification 
was carried out as follows: 10s at 95°C, 15 seconds at 60°C, 20s at 72°C for 45 cycles. The 
amount of immunoprecipitated DNA in each sample was determined as fraction of input 
[amplification efficiency^(Ct INPUT-Ct ChIP)], and normalized to IgG control. Primers are 
listed in TABLE 4. 
For ChIP-seq, ~200 µg of chromatin were incubated with 10 µg of antibody overnight at 4°C. 
Antibody/antigen complexes were recovered with ProteinA-Dynabeads (Invitrogen) for 2h at 
4°C. Two large scale preparations of chromatin immunoprecipitated with various antibodies 
(and their Input chromatin) were prepared. Library preparation and sequencing were 
performed at the Istituto di Genomica Applicata (Udine). DNA concentration was determined 
with a fluorometric assay (Quant-iT™ DNA Assay Kit, high sensitivity, Life 
Technologies) and 2-3 ng served as template to generate the library with Ovation Ultra Low 
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Library Prep Kit (NuGEN) according to manufacturer's instructions. Sequencing was 
performed with Illumina HiSeq2500. About 60 mln sequences per sample were obtained. 
 
Chromatin conformation capture (3C) 
Adherent cells were incubated with a solution containing 1.5% formaldehyde for 10 min at 
room temperature, followed by 5 min treatment with 0.125 M glycine/PBS. Cells were 
incubated with 0.05% trypsin for 10 min at 37 °C, before completely detaching them with a 
cell scraper. Collected cells were pelletted, washed in PBS and incubated with lysis buffer for 
15 min at 4 °C. Nuclei were digested with HindIII restriction enzyme (NEB), and highly 
diluted digested chromatin was ligated with T4 DNA ligase (NEB). De-crosslinked DNA 
fragments were purified by phenol–chloroform extraction and ethanol precipitation. A 
reference template was generated by digesting, mixing and ligating bacterial artificial 
chromosomes spanning the genomic regions of interest. 3C templates and the reference 
template were used to perform semiquantitative PCR with GO Taq G2 Flexi DNA 
Polymerase (Promega). Primers flanked the HindIII restriction sites located close to MYC and 
TOP2A promoters (anchors) and enhancers (primer sequences are provided in TABLE 5). 
Data are presented as the ratio of amplification obtained with 3C templates from MDA-MB-
231 cells and with the reference template. PCR performed on control 3C template obtained 
from not-crosslinked cells never yielded any product. PCR products were verified by 
sequencing. 
 
Bioinformatic analysis was carried out in the lab of Prof. Bicciato in Modena University by 
Mattia Forcato PhD.  
 
Peak Calling and Data Analysis 
Uniquely-mapping, non redundant reads were aligned using Bowtie (version 0.12.7) to build 
version hg19 of the human genome (GRCh37/hg19). Redundant reads were removed using 
SAMtools. The IDR (Irreproducible Discovery Rate) framework was used to assess the 
consistency of replicate experiments and to obtain a high confidence single set of peak calls 
for each Transcription Factor as described in the ChIP-seq guidelines of the ENCODE 
consortium. MACS2 version 2.0.10 was used to call peaks in individual replicates using IgG 
ChIP-seq as control sample and an IDR threshold of 0.01 was applied for all datasets to 
identify an optimal number of peaks.  
Normalized read density (reads per million, rpm) was calculated from pooled replicates using 
MACS2 callpeak function and displayed using Integrative Genomics Viewer (IGV). 
Heatmaps were generated using a custom R script which considers a 2-kb window centered 
on peak summits and calculates the normalized reads density with a resolution of 50 bp. The 
genomic location of the peaks and their distance to TSS of annotated genes were calculated 
using annotatePeakInBatch function of ChIPpeakanno R package and GENCODE annotation 
version 16. Only genes classified as protein coding and with status equal to KNOWN were 
considered.  
The findOverlappingPeaks function of the same package was used with default parameters to 
identify overlapping peaks and calculate the distance between their summits. TAZ peaks 
coordinates and summit positions were used to represent common peaks between YAP and 
TAZ peaks (YAP/TAZ peaks) and were used when comparing YAP/TAZ peaks with other 
ChIP-seq data. 
 
Definition of MDA-MB-231 promoters and enhancers 
Raw reads for ChIP-seq data of histone modifications (H3K4me1, H3K4me3 and H3K27ac) 
in MDA-MB-231 were downloaded from SRA (SRP028597) and aligned using Bowtie 
version 0.12.9 to build version hg19 of the human genome retaining only uniquely mapped 
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reads. Redundant reads were removed using SAMtools. Peak calls and read density tracks 
were generated using SPP version 1.11 with default parameters and using as control sample 
the IgG ChIP-seq data generated in our laboratory because of the low sequencing depth of the 
Input DNA contained in SRP028597. The distance between histone modifications peaks and 
the transcription start sites (TSS) of protein coding genes (GENCODE v. 16 and REFSEQ 
annotations), and the overlap between histone marks peaks were calculated as previously 
described for TF peaks. The presence of H3K4me1 and H3K4me3 peaks, their genomic 
locations and their overlap were the criteria used to define promoters and enhancers: i) 
H3K4me3 peaks not overlapping with H3K4me1 peaks and close to a TSS (± 5kb) were 
defined as promoters, as NA otherwise; ii) H3K4me1 peaks not overlapping with H3K4me3 
peaks were defined as enhancers; iii) regions with the co-presence of H3K4me1 and 
H3K4me3 peaks were visually inspected on IGV and were defined as promoters, enhancers or 
NA after the evaluation of the proximity to a TSS and the comparison of the enrichment 
signals. Finally, promoters or enhancers were defined as active if overlapping with H3K27ac 
peaks.  
 
YAP/TAZ peaks annotation 
YAP/TAZ peaks were annotated as promoters or enhancers if their summit was overlapping 
with promoter or enhancer regions as defined above. Peaks with the summit falling in regions 
with no H3K4me1 or H3K4me3 peaks, or in NA regions were defined as "not assigned" and 
discarded from subsequent analyses.  
YAP/TAZ peaks summits were compared with FAIRE peaks using the list downloaded from 
GSE49651. 
YAP/TAZ peaks falling on promoters were assigned to the closest TSS. YAP/TAZ peaks 
falling on active enhancers were annotated using the chromatin interactions reported in Jin et 
al, derived from a high resolution Hi-C experiment; the data sheets report the genomic 
locations of all target peaks interacting with more than 10 thousands anchors located at gene 
promoters. YAP/TAZ peaks overlapping with these target peaks were assigned to the 
corresponding interacting promoter region. Finally, YAP/TAZ peaks falling on inactive 
enhancers were not assigned to targets.  
 
Motif discovery in ChIP-seq peaks 
De novo motifs discovery was performed with findMotifsGenome function of Homer 
software. Motifs were searched in 500 bp windows centered at the peak summits. 
Occurrences of de novo and known motifs inside the peaks were found using annotatePeaks 
function of the same software. Known motifs were retrieved from Homer motif database and 
from JASPAR database (http://jaspar.genereg.net). 
 
Gene Ontology analysis 
Gene Ontology (GO) analyses were performed using DAVID. GO terms with a Benjamini-
Hochberg FDR ≤ 5% were considered significantly enriched. GO terms significantly enriched 
among YAP/TAZ direct positive target genes could be assigned to two broad categories: “cell 
proliferation” and “RNA metabolism and transport”.  
Promoters of the genes involved in cell proliferation were defined as 1000 bp windows 
centered at the TSS. De novo motifs discovery and occurrence of known motifs were 
performed as described above. Used known motifs are E2F4(E2F) from Homer motif 
database and (MA0024.1) for E2F1 from JASPAR database. 
 
Analysis of public ChIP-seq data 
ChIP-seq datasets for histone modifications that were re-analyzed in this study are from Rhie 
et al.  
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For data of the ENCODE project, aligned reads and peak calls were downloaded from the 
ENCODE project repository. When available, TF peaks uniformly generated by the ENCODE 
Analysis Working Group (available at 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeAwgTfbsUniform/) 
were used. Otherwise, aligned reads and peak calls of the first replicate were used. Genomic 
annotation of TEAD4 or TEAD1 peaks and overlap between peaks were calculated as 
described for ChIP-seq data of MDA-MB-231 cells. 
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FIGURES 
Figure 1. ChIP-sequencing method 
 
A. Schematic workflow of a chromatin-immunoprecipitation (ChIP) experiment. 
B. Electrophoretic gel to control size of chromatin fragments after sonication that should 
be between 200-600bp. 
C. Sequence of passages that illustrates the alignment of sequenced tags to the genome, 
resulting in two peaks that flank the binding region of the protein of interest. 
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Figure 2. Chromatin immunoprecipitation of endogenous YAP/TAZ  
 
A. Immunoblot to control the result of the immunoprecipitation from MDA-MB-231 
crosslinked cells. Chromatin immunoprecipitated with anti-YAP antibody is enriched 
with YAP protein, while chromatin immunoprecipitated with anti-TAZ antibody is 
enriched with TAZ and YAP proteins. Chromatin immunoprecipitated with pre-
immune rabbit IgG, used as control, is not enriched with YAP and TAZ proteins. 
B. qPCR of ChIPed DNA to verify the enrichment of known YAP/TAZ-bound 
sequences (CTGF and Cyr61 promoters), that are immunoprecipitated by YAP and 
TAZ from control cells, but not from YAP/TAZ-depleted cells or negative control 
ChIPs with pre-immune rabbit IgGs. A genomic fragment belonging to the β-globin 
locus is negative control locus. Relative DNA binding was calculated as fraction of 
input and normalized to IgG. Data are presented as mean + SD of two independent 
replicates. 
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Figure 3. YAP/TAZ ChIP-sequencing 
 
A. Deep sequencing results of ChIPed DNA samples. Two independent experiments were 
performed (#1, #2). IP YAP/TAZ corresponds to IP with anti-TAZ antibody. 
B. Venn diagrams showing the overlap of peaks identified in ChIP-seq experiments with 
YAP and TAZ antibodies. Overlapping peaks are defined YAP/TAZ peaks. 
C. ChIP-seq profiles of YAP and TAZ peaks at positive control loci and other known 
YAP/TAZ-regulated genes. YAP and TAZ peaks were present on the investigated 
promoters, whereas negative control sample (IgG) displayed few tags aligned with the 
same regions, without any appreciable difference with background noise. 
D. ChIP-qPCR to validate YAP/TAZ binding sites identified through ChIP-seq. 
ANKRD1, Axl, AMOTL2, AJUBA and WTIP sequences (but not a negative control 
locus, data not shown) were enriched in YAP- and TAZ-immunoprecipitated 
chromatin, but not in negative control IP (IgG) or in chromatin obtained from 
YAP/TAZ-depleted cells. Relative DNA binding was calculated as fraction of input 
and normalized to IgG. Data are presented as mean + SD of two independent 
replicates. 
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Figure 4. Distribution of YAP/TAZ binding sites in the genome 
 
A. Graphical representation of YAP/TAZ peaks distribution in the genome, with 
respect to protein coding genes deposited in the Gencode database. Peaks were 
associated to a gene if they laid within 1 kb upstream or 1 kb downstream of the 
transcription start site (TSS). 
B. Distribution of YAP/TAZ ChIP-seq peaks relative to the closest TSS; ~85% of 
peaks were located farther than 10kb from the closest TSS. 
C. ChIP-seq profile showing examples of YAP/TAZ peaks categorized as 
"promoters", "active enhancers", "inactive enhancers" or not classified, based on 
published ChIP-seq data for histone modifications.  
D. Graphical representation showing the fraction of YAP/TAZ peaks associated with 
each category: promoters, active enhancers, inactive enhancers or not classified.  
E. Percentage of peaks within each category (promoters, active enhancers, inactive 
enhancers or not classified) localized in nucleosome-depleted regions, defined by 
Formaldehyde-assisted identification of regulatory elements followed by deep 
sequencing (FAIRE). 
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Figure 5. Association of YAP/TAZ peaks 
 
Graphical representation of the procedure used to identify candidate YAP/TAZ direct target 
genes. 
A. YAP/TAZ peaks located close to a TSS (± 5kb), and whose summit was overlapping 
with H3K4me3 peaks, were assigned to the nearest gene. 
B. YAP/TAZ peaks located in enhancer regions, and whose summit was overlapping 
with H3K4me1 peaks, were assigned to promoters that can physically interact with 
them according to high resolution chromatin conformation capture data. 
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Figure 6. Identification of YAP/TAZ direct target genes 
 
A. Overview of gene expression data obtained by Affymetrix Microarrays on MDA-MB-
231 cells, transfected with two different mixes of YAP/TAZ siRNAs and compared to 
control siRNA.  
B. Distance between YAP/TAZ binding sites and the TSS of the direct target genes they 
are associated to. 58% of YAP/TAZ-occupied enhancers are located farther than 
100,000 bp from the corresponding TSS 
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Figure 7. YAP/TAZ regulate a transcriptional program driving cell growth  
 
A. Graphical representation of the biological functions associated to YAP/TAZ direct 
positive targets, identified by Gene Ontology (GO) analysis. By DAVID (Database for 
Annotation, Visualization and Integrated Discovery), 36% of YAP/TAZ targets 
resulted to be linked with cell cycle progression and 14% of the total are connected to 
RNA metabolism and RNA transport. No other biological processes were significantly 
regulated by YAP/TAZ. 
B. mRNA levels of several candidate YAP/TAZ target genes involved in cell 
proliferation were evaluated by qRT-PCR using TaqMan Low Density Arrays, in cells 
transfected with control (siCO) or two pairs of YAP/TAZ siRNAs (siYT1, siYT2). 
mRNA levels were normalized to GAPDH. 
C. Immunoblot on protein extract of MDA-MB-231 cells, to verify a subset of YAP/TAZ 
target genes, upon the depletion of YAP/TAZ by transfection with two different 
YAP/TAZ siRNAs, compared to a control siRNA (siCO). GAPDH is used as loading 
control. 
D. ChIP-qPCR on MDA-MB-231 cells to verify YAP and TAZ binding to a subset of 
enhancers associated with a YAP/TAZ target genes. Relative DNA binding was 
calculated as fraction of input and normalized to IgG. Data from 2 biological 
replicates are shown. Negative control locus displayed background signal  (data not 
shown). 
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Figure 8.  YAP/TAZ enhancers contact MYC and TOP2A promoters via chromatin 
looping 
 
A. ChIP-seq profiles showing the position of YAP and TAZ binding sites (named "MYC 
enhancer 1", “MYC enhancer 4”) associated to MYC gene; no YAP/TAZ binding sites 
were detected close to its TSS. 
B. C. Validation of the long-range interaction between YAP/TAZ-bound enhancers and 
the promoters of MYC (B) and TOP2A (C) by DNA looping, using 3C assay. The chart 
shows the frequency of interaction (measured as cross-linking frequency) between 
MYC or TOP2A promoter ("anchor") and the indicated sites surrounding YAP/TAZ 
peaks (green lines). Interaction frequency is higher close to YAP/TAZ peak. Data 
points are mean + SEM from 3 replicates. 
D. ChIP-qPCR on MDA-MB-231 cells to compare H3K27ac levels (normalized to total 
H3 levels) in cells transfected with control (siCO) or YAP/TAZ siRNAs (siYT). Data 
are mean + SD of two replicate samples. 
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Figure 9. MYC is a mediator of YAP/TAZ-induced proliferation in breast cancer cells 
 
A. Immunoblot on MDA-MB-231 protein extract to verify the downregulation of MYC 
after transfection with two different MYC siRNAs (siMYC1 and siMYC2), compared 
to a control siRNA (siCO). GAPDH is used as loading control. 
B. Growth curve of MDA-MB-231 cells transfected with siCO or two different MYC 
siRNAs (siMYC1 and siMYC2). Cell growth is evaluated by crystal violet staining. 
At day 6 after transfection, we can see a decrease in proliferation of MYC depleted 
cells compared to control. Data are mean+SD of n= 8 biological replicates. 
C. Percentage of MDA-MB-231 cells in G1, S and G2/M phases of the cell cycle, as 
determined by flow-cytometric analysis of DNA content. Cells were transfected with 
control siRNA (siCO) or MYC siRNAs (siMYC1 and siMYC2) 48h before fixation. 
Transfection of MYC siRNAs leads to G1 arrest. Data are mean + SD of three 
biological replicates. 
D. Immunoblot on protein extract of MDA TetON EGFP (left), MDA TetON MYC-
transduced cells (right) to verify the proper functioning of Tet-ON expression system. 
EGFP or MYC are expressed only in cells treated with Doxycycline (‘+doxy’). 
GAPDH using as a loading control. 
E. Growth curve and cell cycle phases analysis in MDA TetON EGFP and MDA TetON 
MYC transduced cells, after transfection of control siRNA (siCO) or a combination of 
YAP and TAZ siRNAs (siYT). Where indicated, EGFP or MYC expressions were 
induced with 0.1 μg/ml Doxycycline at the time of transfection. Cell growth (left 
panel) is evaluated by crystal violet staining. Data are mean+SD of n=8 biological 
replicates. Cell cycle phases are determined by flow-cytometric analysis of DNA 
content, in cells fixed 48h after transfection of siRNAs. Data are mean + SD of three 
biological replicates. MYC overexpression, but not EGFP, can rescue the growth and 
G1-block of YAP/TAZ depleted cells.  
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Figure 10. Genome-wide recruitment of YAP/TAZ to chromatin through TEAD factors 
 
A. Most recurrent motif in YAP/TAZ-bound sequences identified by de novo motif 
finding, corresponding to a TEAD binding site. 
B. Graphical representation of YAP/TAZ peaks percentage containing at least one known 
TEAD-binding motif.  
C. Position of TEAD motif relative to the summit of YAP/TAZ peaks. Graph shows the 
density of TEAD motifs at each position in a 500 bp window surrounding the summit 
of the corresponding YAP/TAZ peaks. TEAD motif frequently occupied the summit 
of YAP/TAZ peaks. 
D. ChIP-qPCR to validate the specificity of TEAD4 antibody on control (siCO) and 
TEAD4-depleted MDA-MB-231 cells (siT4). Selected loci were enriched in TEAD4-
immunoprecipitated chromatin, but not in negative control IP (IgG) or in chromatin 
obtained from TEAD4-depleted cells. Data are presented as mean + SD of two 
independent replicates. 
E. Venn diagram showing the overlap of YAP/TAZ and TEAD4 peaks. 5522 YAP/TAZ 
binding sites (78%) overlapped with TEAD4 peaks. 
F. Position of TEAD4 peaks relative to YAP/TAZ peaks. Graph shows the density of 
TEAD4 peak summit at each position in a 500 bp window surrounding the summit of 
the corresponding YAP/TAZ peaks. Summits of TEAD4 peaks are located at the 
summits of the corresponding YAP/TAZ peaks. 
G. ChIP-seq profiles showing co-occupancy of CTGF, ANKRD1 and Axl promoters by 
YAP, TAZ and TEAD4 in MDA-MB-231 cells. 
H. Strong linear correlation resulting from measuring peak signals between the strengths 
of YAP (or TAZ) and TEAD4 peaks in the 5522 shared binding sites.  
I. ChIP-qPCR showing YAP binding to ANKRD1 and Axl promoters in MDA-MB-231 
cells transfected with control (siCO) or TEAD siRNAs (siTEAD). Relative DNA 
binding was calculated as fraction of input and normalized to IgG (IgG bars are 
omitted). Data are presented as mean + SD of two independent replicates. 
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Figure 11. YAP/TAZ transcriptional and biological effects depended on TEAD factors  
 
A. qRT-PCR to measure mRNA levels (normalized to GAPDH) for TEAD1-4 in MDA-
MB-231 cells transfected with two different mixes of TEAD1-4 siRNAs (siTEAD A 
or siTEAD B) or control siRNA (siCO). Data are presented as mean + SD of two 
biological replicates. The efficiency of TEAD depletion was also evaluated by qRT-
PCR for the expression of the YAP/TAZ/TEAD targets CTGF and ANKRD1. 
B. mRNA levels of several candidate YAP/TAZ target genes involved in cell 
proliferation were evaluated by qRT-PCR using TaqMan Low Density Arrays, in cells 
transfected with control (siCO) or TEAD siRNAs (siTEAD A and B). mRNA levels 
were normalized to GAPDH. 
C. Growth curve of MDA-MB-231 cells transfected with control siRNA (siCO) or TEAD 
siRNAs (siTEAD A or siTEAD B). Cells were harvested at the indicated time points 
after siRNA transfection, and their amount was evaluated by crystal violet staining. 
Data are mean + SD of 8 technical replicates. 
D. Cell cycle phases of MDA-MB-231 cells transfected with control siRNA (siCO) or 
TEAD siRNAs (siTEAD A or siTEAD B). Percentage MDA-MB-231 cells in G1, S 
and G2/M phases of cell cycle are determined by flow-cytometric analysis of DNA 
content, in cells fixed 48h after transfection of siRNAs. Data are mean + SD of three 
biological replicates.  
E. Histogram shows growth rate of empty vector and YAP-transduced MDA-MB-231 
cells, after transfection of control siRNA (siCO) or a combination of YAP and TAZ 
siRNAs (siYT 1). Sustained expression of YAP wild-type (wt), but not of TEAD-
binding deficient YAPS94A, rescues cell proliferation in YAP/TAZ-depleted cells. 
Cells were harvested 24h or 6 days after siRNA transfection. Data are mean + SD of 8 
technical replicates. 
F. Histogram shows growth rate of empty vector and TAZ-transduced MDA-MB-231 
cells, after transfection of control siRNA (siCO) or a combination of YAP and TAZ 
siRNAs (siYT 1). Sustained expression of TAZ wild-type (wt), but not of TEAD-
binding deficient TAZS51A, rescues cell proliferation in YAP/TAZ-depleted cells. 
Cells were harvested 24h or 5 days after siRNA transfection. Data are mean + SD of 8 
technical replicates. 
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Figure 12. YAP/TAZ/TEAD interact with BRD4  
 
A. Immunoblot showing YAP, TEAD1 and BRD4 co-precipitation at endogenous protein 
level from MDA-MB-231 nuclear extracts. Aspecific IgGs are used as negative 
control. 
B. Detection of endogenous BRD4/TEAD1 interactions in MDA-MB-231 cells by in situ 
PLA (proximity ligation assay). PLA was performed for the indicated protein dimers, 
and nuclei were counterstained with DAPI (blue). The detected dimers are represented 
by fluorescent dots (red). As control of the specificity of the interactions, no dots 
could be detected in the nuclei when we performed the PLA omitting either of the 
primary antibodies (data not shown).   
C. Immunoblot showing isolated proteins captured by HA-BRD4 resin. HA-BRD4 
protein was overexpressed in HEK293T cells and immobilized by anti-HA antibodies 
on protein A-agarose beads. HA-BRD4-loaded resin was incubated with FLAG-
tagged YAP, TAZ, or TEAD1 isolated from HEK293T protein extracts. FLAG-YAP 
interacted with HA-BRD4 only in the presence of FLAG-TEAD1 (arrow), whereas 
FLAG-TAZ showed a tiny interaction with BRD4 and a stronger binding in the 
presence of FLAG-TEAD1. 
D. Immunoblot showing isolated proteins captured by HA-YAP resin. HA-YAP resin 
was incubated with FLAG-tagged BRD4 and/or TEAD1. Bottom box: picture taken 
with a higher sensitivity detection reagent. FLAG-BRD4 interacted with HA-YAP 
only in the presence of FLAG-TEAD1.   
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Figure 13. BRD4 binds and regulated the cis-regulatory elements of YAP/TAZ/TEAD 
target genes 
 
A. ChIP-qPCR to validate the specificity of BRD4 antibody on control (siCO) and 
BRD4-depleted MDA-MB-231 cells (siBRD4). Selected enhancer regions (CDC6 and 
TOP2A) were enriched in BRD4-immunoprecipitated chromatin, but not in negative 
control IP (IgG) or in chromatin obtained from BRD4-depleted cells. Relative DNA 
binding was calculated as fraction of input and normalized to IgG. 
B. ChIP-qPCR to verify BRD4 binding on the promoters (TSS) and enhancers of 
established YAP/TAZ direct targets. BRD4 immunoprecipitated selected loci, but not 
negative control locus, from MDA-MB-231 cells cells. Relative DNA binding was 
calculated as fraction of input and normalized to IgG (negative control IP). 
C. Unsupervised hierarchical clustering of MDA-MB-231 RNA-sequencing samples. 
Data from 2 biological replicates. 
D. Venn diagrams showing the overlap between YAP/TAZ target genes and JQ1 
sensitive genes identified by RNA-seq experiment. 68% of YAP/TAZ targets are also 
sensitive to JQ1.  
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Figure 14. BRD4 is instrumental for YAP/TAZ biological activity 
 
A. Immunoblot showing the efficiency of BRD4 shRNAs in MDA-MB-231 cells by 
doxycycline treatment for 5 days. GAPDH serves as loading control. 
B. MDA-MB-231 colonies formation in soft agar assay after BRD4 downregulation by 
doxycycline shRNA expression. 3*104  cells/well were plated into soft agar in the 
absence or presence of doxycycline and allowed to grow for 3 weeks. BRD4 
knockdown reduce the number of colonies formed by MDA-MB-231 cells. Three 
replicates were analyzed for each sample; data are presented as mean + SD. 
C. Immunoblot showing esogenous constitutive YAP expression and the efficiency of 
inducible BRD4 shRNAs by doxycycline treatment for 5 days in MCF10A cells. 
GAPDH serves as loading control.  
D. MCF10A colonies formation in soft agar assay dependent on YAP expression, in 
presence or absence of BRD4; BRD4 downregulation is induced by doxycycline-
dependent expression of shRNAs. 104 cells/well were plated into soft agar in the 
absence or presence of doxycycline and allowed to grow for 3 weeks. YAP 
overexpression conferred MCF10A cells the capacity to seed colonies with high 
efficiency; BRD4 shRNAs reduced colony formation compared to cells expressing 
both YAP5SA and shCO. Three replicates were analyzed for each sample; data are 
presented as mean + SD. 
E. MDA-MB-231 colonies formation in soft agar assay after treatments for three weeks 
with different doses of JQ1 inhibitor. Colonies did not grow at the lowest inhibitor 
concentration compare to vehicle (DMSO). Three replicates were analyzed for each 
sample; data are presented as mean + SD. 
F. MCF10A colonies formation in soft agar assay dependent on YAP expression, after 
treatments with different doses of JQ1 inhibitor for three weeks. YAP5SA-
overexpressing cells show a dose-dependent growth compare to vehicle (DMSO). 
Three replicates were analyzed for each sample; data are presented as mean + SD. 
G. MCF10A colonies formation in soft agar assay dependent on YAP expression to 
verify if JQ1 affected colony progression, beyond colony initiation. JQ1 treatment 
started at different time points: at the moment of seeding, or 7 or 15 days later. Also 
after 15 days, fewer cells grew enough to form sizable colonies. Three replicates were 
analyzed for each sample; data are presented as mean + SD. 
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Figure 15. JQ1 does not affect BRD4-TEAD interaction and YAP/TAZ recruitment on 
enhancers 
 
A. Immunoblot showing isolated proteins captured by HA-BRD4 resin. HA-BRD4 resin 
was incubated with FLAG-tagged TEAD1 in presence or absence of JQ1 1μM 
inhibitor in the reaction buffer. HA-BRD4 was able to capture FLAG-TEAD1 also in 
the presence of JQ1. 
B. Immunoblot showing YAP, TEAD1 and BRD4 co-precipitation at endogenous protein 
level from MDA-MB-231 cells, upon DMSO (control), JQ1 1μM or PFI-1 10μM 
treatment for 6hours. Aspecific IgGs are used as negative control. TEAD1 and YAP 
co-precipitated with BRD4 also in the presence of BET-inhibitors. 
C. ChIP-qPCR to verify YAP/TAZ binding on enhancers of established YAP/TAZ direct 
targets in MDA-MB-231 cells treated with 1μM JQ1 for 6h (or DMSO as control). 
Anti-TAZ antibody immunoprecipitated selected loci from MDA-MB-231 cells cells 
also in the presence of JQ1. Negative control locus displayed background signal  (data 
not shown). Relative DNA binding was calculated as fraction of input and normalized 
to DMSO. 
D. ChIP-qPCR verifying release of BRD4 from promoters and enhancers of established 
YAP/TAZ direct targets, upon JQ1 1μM treatment for 3, 6 or 24 hours. BRD4 binding 
is reduced in the presence of JQ1 at 3 and 6 hours of treatment. Negative control locus 
displayed background signal  (data not shown). Relative DNA binding was calculated 
as fraction of input and normalized to DMSO.  
 
 
 
 
 
 
 
 
 
 
 
 
	   79	  
 
 
 
 
 
In
pu
t  
+ 
+ 
HA  
(BRD4) 
Flag 
 (TEAD1) 
Flag-TEAD1 
JQ-1 10uM 
+ + - 
- + - 
HA-BRD4 resin 
Figure 15 
D
M
S
O
 
JQ
1 
µM
 
P
FI
-1
 1
0µ
M
 
D
M
S
O
 
IP:BRD4 R
-Ig
G
 
Input 
D
M
S
O
 
JQ
-1
 1
µM
 
P
FI
-1
 1
0µ
M
 
YAP 
TEAD1 
BRD4 
0 
0,2 
0,4 
0,6 
0,8 
1 
1,2 
1,4 
ANKRD1 CDC6 
Enh 
CDC6 
TSS 
TOP2A 
Enh 
TOP2A 
TSS 
CCNA2 
Enh 
CCNA2 
TSS 
GINS1 
Enh 
GINS1 
TSS 
R
el
at
iv
e 
D
N
A 
bi
nd
in
g 
IgG DMSO JQ1 3h JQ1 6h JQ1 24h 
0 
0,2 
0,4 
0,6 
0,8 
1 
1,2 
ANKRD1 CDC6 Enh CCNA2 
Enh 
TOP2A 
Enh 
GINS1 
Enh 
R
el
at
iv
e 
D
N
A 
bi
nd
in
g 
IgG DMSO JQ1 1uM 
A B 
C 
D 
 YAP/TAZ 
ChIP-qPCR 
 BRD4 
ChIP-qPCR 
JQ1 1µ  
µ
	   80	  
Figure 16. Loss of BRD4 impairs Pol II recruitment on YAP/TAZ/TEAD-regulated 
genes 
 
A. Immunoblot on protein extract of MDA-MB-231 cells, to verify phosphorylation state 
of Pol II, upon the depletion of YAP/TAZ or BRDs by transfection with siRNAs, or 
JQ1 1µM treatment (24 hours) compared to a control siRNA (siCO). Phosphorylation 
of Pol II on Ser2 was reduced in all conditions compared to siCO. GAPDH is used as 
loading control. 
B. ChIP-qPCR verifying Pol II binding to promoters of established YAP/TAZ direct 
targets upon downregulation of YAP/TAZ (siYAP/TAZ) or BRDs (siBRDs), or JQ1 
1μM treatment for 24hours. GAPDH promoter represents a non-YAP/TAZ target. 
Negative control immunoprecipitation by IgG displayed background signal  (data not 
shown). DNA enrichment was calculated as fraction of input. 
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TABLE 1  
 
 
ABHD10 CKAP2L GLTP MRPL46 PSMC3IP SSR3
ACAT2 CMIP GNL2 MRPL52 PSMG1 SUV39H2
ADAMTS16 CNIH GNL3 MRPL9 PSRC1 TAF5L
ADAMTS6 COL12A1 GPATCH4 MRRF PSTPIP2 TBC1D2
ADRB2 CORO1C GPN3 MTA2 PTGER2 TBC1D4
AFAP1L1 CRIM1 GRPEL1 MTFP1 PTPLA TBCE
AIMP2 CRY1 GTPBP4 MTG1 PTPN2 TCOF1
AJUBA CSE1L HAT1 MTHFD1 PTRH2 TCP1
AKAP12 CSPP1 HAUS4 MTPAP PTX3 TDP1
AMOTL2 CTGF HBEGF MUTYH RAB11FIP1 TEAD4
ANKRD1 CTNNAL1 HIST1H3B MYBL1 RABGEF1 THG1L
ANKRD32 CUTC HNRNPM MYC RAD18 THOC1
ANKRD33B CYC1 HSPA14 NAA15 RALGPS2 THOC6
ANXA3 CYP20A1 HSPA9 NAA25 RBL1 TIMELESS
APITD1 CYR61 HYI NASP RBM22 TIMM10
ARNTL2 DARS2 ICK NAT10 RBM24 TIMM8A
ARSJ DDAH1 IGFBP3 NCBP2 RCAN1 TK1
ASAP1 DDX21 IL12A NCL RCC1 TMEM106C
ASB1 DDX46 ILF3 NEDD4L RHEB TMEM194A
ATAD2 DDX47 IQGAP3 NEIL2 RND3 TMEM200B
ATG3 DDX56 IRAK1 NEURL1B RNMTL1 TMEM201
AXL DEK ISG20L2 NFKB1 RPF2 TMEM209
B3GALNT2 DIAPH3 ITGB2 NMT2 RPL27A TNFRSF12A
BANF1 DIS3L KATNB1 NOB1 RPL3 TOE1
BASP1 DKC1 KIAA0391 NOC3L RPP40 TOP2A
BCAT1 DKK1 KIAA1524 NOL10 RPUSD2 TRA2B
BCS1L DNAJA3 KIF14 NOP14 RQCD1 TRDMT1
BOD1 DNTTIP2 KIF18B NPM3 RRM2 TRIM14
BTBD10 DPH5 KIF20B NUDCD1 RRP1B TRIP6
BUB1B DTYMK KIF23 NUF2 RRS1 TRMT1
C11orf48 DUSP14 KIF2C NUP188 RTN4IP1 TRMT5
C11orf83 E2F3 KLHDC4 NUP50 RUVBL2 TROAP
C12orf45 EDN1 KNTC1 NUP85 SAMD4A TSEN2
C12orf65 EFTUD2 LARP4 NUP88 SART3 TTI1
C17orf89 EID2 LARP4B NUP93 SEH1L TUBB
C1orf109 EIF3D LAYN NXT1 SEPT11 TUBB6
C1QBP EIF3J LEPREL1 ODC1 SERPINE1 TUBG1
C4BPB EIF4EBP1 LIMA1 OXNAD1 SERTAD2 U2AF1
C5orf28 EIF5A2 LMNB2 PABPC4 SERTAD4 UBE2E2
C9orf142 ENC1 LRIG3 PAK1IP1 SET UBE2G2
C9orf40 ERCC6L LRRC8C PANK2 SF3A3 UBR4
CASC5 ERLIN1 LSG1 PAWR SF3B3 UCK2
CCDC137 ETS1 LSM3 PCID2 SFXN4 URB2
CCDC15 ETS2 LZIC PDCD5 SGOL1 USP36
CCDC85C EXOSC2 MAD2L1BP PHACTR1 SHMT2 USP44
CCNA2 F3 MAGOHB PHF17 SLC1A5 UTP15
CDC25A FAM46B MALSU1 PHTF2 SLC25A32 UTP20
CDC42EP3 FAM57A MAP3K1 PKN3 SLC35F3 WDR67
CDC6 FAM89A MATN2 PKP4 SLC41A1 WDR74
CDCA4 FARSA MCM3 PLAU SLMO1 WDR85
CDCA5 FGF5 MCM7 PNPT1 SMC3 WSB2
CDCA8 FJX1 MED27 POC1A SMTN WTIP
CDH4 FLG MED30 POLA2 SNAI2 WWC1
CDKN2AIPNLFOSL1 MEST POLE3 SNAPC1 WWC2
CENPF FOXF2 METAP2 POLH SNRPD2 XPO5
CENPL FST METTL12 POLR1A SNRPF XPO6
CENPV FTSJ2 METTL13 POLR1C SOAT1 YOD1
CEP152 GADD45A METTL8 PPIF SOCS2 ZCCHC8
CEP290 GADD45B MIIP PPME1 SPATA5L1 ZMYND19
CEP55 GADD45GIP1MRE11A PPRC1 SRBD1 ZNF259
CEP57 GEMIN4 MRPL18 PRMT1 SRRD ZNF804A
CEP57L1 GINS1 MRPL21 PRMT5 SRSF2 ZNHIT6
CHUK GJA1 MRPL24 PRPF4 SRSF3 ZWILCH
List of YAP/TAZ/TEAD direct target genes
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TABLE 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Company Catalog Number Description Use
normal rabbit IgG sigma aldrich I5006 - IgG from rabbit serum ChIP, IP
normal mouse IgG santa cruz sc-2025 ChIP, IP
anti-YAP1 abcam ab52771 Rabbit monoclonal ChIP
anti-TAZ (WWTR1) sigma aldrich HPA007415 Rabbit polyclonal ChIP
anti-YAP1 Proteintech 13584-1-AP Rabbit polyclonal IP,PLA
anti YAP/TAZ (63.7) santa cruz sc-101199 Mouse monoclonal IB
anti-TEAD4 (TEF-3 antibody N-G2)santa cruz sc-101184 Mouse monoclonal ChIP
anti-TEF1 BD Biosciences 610923 Mouse monoclonal IB, PLA
anti-Histone H3 abcam ab1791 Rabbit polyclonal ChIP
anti-Histone H3 (acetyl K27) abcam ab4729 Rabbit polyclonal ChIP
anti-BRD4 Bethyl-LAB A301-985A Rabbit polyclonal ChIP
anti-BRD4 Sigma HPA015055 Rabbit polyclonal IB
anti-BRD4 CST E2A7X Rabbit polyclonal IP
anti-Pol II abcam ab817 Mouse monoclonal ChIP, IB
anti-Pol II  P-Ser2 abcam ab5095 Rabbit polyclonal IB
anti-GAPDH millipore MAB374 Mouse monoclonal IB
anti-FOSL1 (Fra-1 R20) santa cruz sc-605 Rabbit polyclonal IB
anti-ARK-1 (H-130) santa cruz sc-25425 Rabbit polyclonal IB
anti-CyclinA (C-19) santa cruz sc-596 Rabbit polyclonal IB
anti-Cdc6 (180.2) santa cruz sc-9964 Mouse monoclonal IB
anti-Ets1 (C-20) santa cruz sc-350 Rabbit polyclonal IB
anti-MCM7 (141.2) santa cruz sc-9966 Mouse monoclonal IB
anti-MCM3 (N-19) santa cruz sc-9850 Goat polyclonal IB
anti-cMyc Cell Signaling Technology 9402S Rabbit polyclonal IB
anti-GFP santa cruz sc-8334 Rabbit polyclonal IB
anti-FLAG M2 sigma aldrich F1804 Mouse monoclonal IB, IP
anti-HA santa cruz sc-7395 Mouse monoclonal IB, IP
ChIP: chromatin immunoprecipitation
IP: immunoprecipitation
IB: immuno blot
PLA : proximity ligation assay
 List of Antibodies
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TABLE  3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name
siCO
siTEAD A
siMYC1
siMYC2
shBRD4 #1 GCCTGGAGATGACATAGTCTTA
shBRD4 #2 ACAGTGACAGTTCGACTGATGA
When the number is not 
specified, mix #1 was used.
When the number is not 
specified, mix #4 was used. 
For BRD4, a mix of anti-
BRD4 siRNAs was used.
shRNA sequences
siBRD #3
siBRD #4
GUAGCAGUGUCACGCCUUA dTdT (BRD2)
CCUGCCGGAUUAUCAUAAA  dTdT (BRD3)
GAGGACAAGUGCAAGCCUA dTdT (BRD4)
GUAGCAGUGUCACGCCUUA dTdT (BRD2)
GCCCGUGGACGCAAUCAAA dTdT (BRD3)
GCGUUUCCACGGUACCAAA dTdT (BRD4)
siRNA sequences
Sequence (5' to 3')
AllStars Negative Control siRNA 1027280 (Qiagen)
siYT 1 GACAUCUUCUGGUCAGAGA dTdT (YAP)
ACGUUGACUUAGGAACUUU dTdT (TAZ)
ACAUCAUCAUCCAGGACUG dTdT
GGUCAGAGUCUGGAUCACC dTdT
siYT 2 CUGGUCAGAGAUACUUCUU dTdT (YAP)
AGGUACUUCCUCAAUCACA dTdT (TAZ)
UGAAUGUGCAAUGAAGCGGCG dTdT
siTEAD B GGCCGAUUUGUAUACCGAA dTdT (TEAD1)
CCUGGUGAAUUUCUUGCACAA dTdT (TEAD2)
UACCUUGCUCUCAAUCUGGAG dTdT (TEAD3)
UUUCCUGCACACACGUCUCUU dTdT (TEAD4)
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TABLE 4 
 
 
 
 
 
Target gene Forward primer Reverse primer
HBB GCTTCTGACACAACTGTGTTCACTAGC CACCAACTTCATCCACGTTCACC
FAT3 GGCTTCCACTTCACACATTCC TGCCCATTCTACTCTGGCTGTT
ANKRD1 AAAAAGGGCAGTGATGTGGTG GAAGAGGGAGGGGAGGACAA
Axl TGAGTAGGGACCAGGGTTGG CCACCACACAGACATGCACA
AMOTL2 TGCCAGGAATGTGAGAGTTTC AGGAGGGAGCGGGAGAAG
AJUBA AGGAAAGAGTGTGGGGGTAGG ACGCTGGGAACAAAGTCACG
WTIP GCAGCGCCGTCTCCTTCCT GCGGCGGAGGAATGTAAGCTC
CTGF TGTGCCAGCTTTTTCAGACG TGAGCTGAATGGAGTCCTACACA
CYR61 CACACACAAAGGTGCAATGGAG CCGGAGCCCGCCTTTTATAC
ETS1 alternative promoter CGTCTGATTCTCCACGCATTC    CGCTCGCCTTCATCCACAT    
Myc enh1 TGCTCCTAAACCTCCTCACCA TGCCCTTGATTTGCTGCTTT
Myc enh4 GGGGAACTCTCACTCTCCTTTGA CCAGGGGGTCTTTACACAGC
Myc enh5 TTCCTGCCTTCTGAGTGGTG TTTCCTGTGACTGCGGGTCT
Myc enh6 AGGGTCCTGGGCTTTTTCAG GGGCCATTCGTCACCTTTTC
TOP2A enh1 GTGGAGTGTGGGCATCTGAG CAATGGGGAAAGAAAGACTGTAGC
TOP2A enh2 CCCCACCCAGACAGGAAA TGAGGCAGGGCAGTTTAGAA
TOP2A enh3 CCGAGGGTTGTTTTCCCATC GACTGTGTGCGTGAGCGTGT
GINS1 enh CCCCAAAAGTGTCCATGACC CAGGATCACCCCCATCTCAA
CCNA2 enh ACAGAAGGGGAGCGACTGG CCCACCGTTTTCACTTTTTC 
FOSL1 enh CTCAGCCACTTCCACCCAGT TCCAGCAGTCTCACCGAATC
CDC6 enh GCTGGGCATCACAGTCTTGG GGCATGGCTGGGTGACTC
KIF23 enh CCCTCACACCCAGAAAGCTG AATCACGCTGGCATTTTGCT
CENPF enh1 CCCCCTCTGCTATTGTTCTCAA TGCCATTTTTCATTCCCACA
CENPF enh2 CCCCACCACCACTGCTTC    GGGAATCTCAGCCTTCTTGG    
MCM3 enh AGTTGGGATAGGCGGAGACC GCAGGTGGGGCTTGTTTAGG
POLE3 enh TGGTTTTTCCGTTCCTGGTG CAGAGGGGAGGGGGTCTATG
RAD18 enh GGCATTTGTGGCATTCCTG    CCTGATCCACTCCACCTTCG    
POLA2 enh ATGACGCTGGACAACAGGAGTC CGACAGAAGAAATCCCTAAGAACC 
ETS1 enh1 CCCTTGTCCCAACACACACA    AAAACTGTCTCCACCTCCTAATGC    
ETS1 enh3 GACACCATCCCCTACAAATGC CACAACTCTCTTTATCAGCAGCACA 
CDCA5 enh AGTGCTGCTCCCCCACACTA CCTGCAAGGAAAGAGCTGGA
CDC6 TSS CAAGGCGAAAGGCTCTGTGA CAAGCCCCTGAACAAACTGC
CCNA2 TSS CCCCTGCTCAGTTTCCTTTGGT TGCAGTTCAAGTATCCCGCGA
TOP2A TSS TTCCTTTAGCCCGCCCGAAG TCCCGCCTCCCTAACCTGAT
GINS1 TSS GCCGAGAGCCCAGATACCAT CGTTGAAGGCAGGCAGTAG
ETS1 TSS CCGCTCCTGAAGAAATGCAC CGTCGATCTCAAGCCGACTC
RRM2 enh AGGGCTGTTGCTCACCTCTTG GCATTCTTCCTGGCTCTTTGTG
RRM2 TSS TTAAAGGCTGCTGGAGTGAGG CGGAGGGAGAGCATAGTGGA
GAPDH TSS TCGCTCTCTGCTCCTCCTGT GTTTCTCTCCGCCCGTCTTC
Target gene Forward primer Reverse primer
GAPDH CTCCTGCACCACCAACTGCT GGGCCATCCACAGTCTTCTG
CTGF AGGAGTGGGTGTGTGACGA CCAGGCAGTTGGCTCTAATC
ANKRD1 AGTAGAGGAACTGGTCACTGG TGGGCTAGAAGTGTCTTCAGAT
TEAD1 GCCTCCCAACATCCATAGCA TCTGTCCACCAGCCGAGATT
TEAD2 TGCCTTCTTCCTGGTCAAGTTC GGCTCTCATACTGGCTGCTCA
TEAD3 GCCGTCTTCTCCACTTCCTC CCAGGGGCTCATAACTGCTG
TEAD4 GGGCAGACCTCAACACCAAC TGTCCATTCTCATAGCGAGCA
 List of primers used for ChIP-qPCR
 List of primers used for qPCR
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TABLE 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anchor CGGTAATGGCAAACGTGAA anchor CCTGGAGAATAAACATCCTTTGC 
Bait 1 AGGTGGCCTTGTGTTAAATGAG Bait 1 GTTGTGCCTTGGTGTGGA 
Bait 2 CAATCTAATGAAGAAAACAAGCAAAG   Bait 2 AGGTCATTCCCTGACTTCTGTT 
Bait 3 TGCACCTGGGGATCTTGT Bait 4 CTATGGCTCTGGAGGAGCTG 
Bait 4 TCAAGGCAAACTATTCCAAGA Bait 5 TCTGCTGGGAGTTACAAGATTTC    
Bait 5 CAAATCTTGTCGAGGAACTAATG Bait 6 GGTGCCTTGTTGTGATGAATTA 
Bait 6 AGGAGAAGAAGGGAACAGGAAG Bait 7 TTGAAGATGGGAATGTGATCTG 
Bait 7 TCCAATAATCTAGTGTGACAGCAAA Bait 8 AGGCACAGAAGCAAGAAACAAT 
Bait 8 AATTGGGAAAGGACTTGGAAAT Bait 9 TTTGCTAATTTCAGTTCTGATTGC 
Bait 9 GGGGAGTACATTAGAGGAACAAA Bait 10 GATGCTGACCTACATTCTTCCTTT 
Bait 10 GCTAATCTTCTATGAGCTTCGTCA Bait 11 CTGAGCTTCTTGGCTTTCAGA 
Bait 11 TAAATACCCCGGCTCCCTTA 
Bait 12 GGCCTCACACCGAATAACTC 
Bait 13 AGGCTGGCTGTTCCTGGT   
Bait 14 GTGTGAAGTGGTTGATGAGAGG 
Bait 1 CAATGGAGGAACCAAAGGTG 
Bait 2 CAGCGACTGCCACAGATAAC 
Bait 3 GCTGTGGTGGGAAAGAAAGATA 
Bait 4 CCACCACCTGAGATACCTGAAT 
Bait 5 TCATAGGGGGAGACAGAAGC 
Bait 6 CCTCCTGGGGAACTCTCA 
Bait 7 GGTGAGTGGGCTTTAGAATGAG 
Bait 8 GTCCTATCAGCCAGAACTTAGCC 
Bait 9 CCTTTATGCCCTCATTTATCCTT 
Bait 10 TTTCCAGAGTTAGGACATGGACA 
Bait 11 CCTCATTTGATCTACAAAGGCTCT 
Bait 12 CTGAAGCAGGAACAGGAGAGAT 
TOP2A (promoter)
TOP2A enhancer 1
MYC (gene)
MYC enhancer 1
MYC enhancer4
 Primers used for 3C assay
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TABLE 6 
 
TaqMan assays 
ANKRD1-Hs00923599_m1 
CCNA2-Hs00996788_m1 
CDC25A-Hs00947994_m1 
CDC6-Hs00154374_m1 
CDCA5-Hs00293564_m1 
CDCA8-Hs00983655_m1 
CENPF-Hs00193201_m1 
CENPV-Hs00396457_m1 
CTGF-Hs01026927_g1 
EDN1-Hs00174961_m1 
ETS1-Hs00428293_m1 
ETS2-Hs01036305_m1 
FOSL1-Hs04187685_m1 
GADD45B-Hs04188837_g1 
GAPDH-Hs99999905_m1 
GINS1-Hs00221421_m1 
KIF14-Hs00208408_m1 
KIF20B-Hs01027505_m1 
KIF23-Hs00370852_m1 
KNTC1-Hs00206854_m1 
MCM3-Hs00172459_m1 
MCM7-Hs00428518_m1 
MRE11A-Hs00967443_m1 
MYBL1-Hs00277143_m1 
MYC-Hs00153408_m1 
POLA2-Hs00160242_m1 
POLE3-Hs00794385_m1 
POLH-Hs00982625_m1 
PSMC3IP-Hs00247433_m1 
PSMG1-Hs00186605_m1 
RAD18-Hs00892551_m1 
RRM2-Hs00357247_g1 
RUVBL2-Hs01090542_m1 
SGOL1-Hs00386282_m1 
SMC3-Hs00271322_m1 
SUV39H2-Hs00226596_m1 
TIMELESS-Hs01086966_m1 
TK1-Hs01062123_m1 
TOP2A-Hs01032137_m1 
TUBB-Hs00962420_g1 
ZWILCH-Hs01555249_m1 
 
 
 
 
